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Congenital hypogonadotropic hypogonadism (CHH) is a rare disease characterized by 
delayed/absent puberty and infertility due to an inadequate secretion or action of gonadotrophin-
releasing hormone (GnRH). CHH is genetically heterogeneous but, due to the infertility of 
affected individuals, most frequently emerges in a sporadic form, though numerous familial 
cases have also been registered. In around 50-60% of cases, CHH is associated with a variety of 
non-reproductive abnormalities, most commonly anosmia/hyposmia, which defines Kallmann 
syndrome (KS) by its presence. Broadly speaking, genetic defects that directly impact on 
hypothalamic secretion, regulation, or action of GnRH result in a pure neuroendocrine phenotype 
called normosmic CHH (nCHH), whereas genetic defects that impact of embryonic migration of 
GnRH neurons to the hypothalamus most commonly result in KS, though nCHH can also arise.  
CHH represents a difficult unresolved puzzle, although more than 25 genes have been described 
to be involved in CHH, molecular variants can explain only 35-45% of reported cases. These 
evidences raise in the last year the idea that CHH is an oligogenic complex genetic disease 
characterized by variable expressivity and penetrance
1
. 
With the purpose to better understand the genetic component of CHH, the first part of this work 
was focused on genetic screening of the principal twelve genes involved in CHH on the largest 
cohort of Italian patients. Screening of a cohort of 512 CHH patients allows the identification of 
204 total variants in 32.2% of clinical cases. The analysis of variants displays a oligogenicity of 
4.6%, confirming the oligogenic nature of CHH. Between the genes that appeared more 
frequently involved in the identified allelic variant, PROKR2 gene appears in 7.5% of the cases. 
Indeed we identified a total of 17 PROKR2 allelic variants, being four novel variants (p.G70S, 
p.D99N, p.C208S, p.M278K). PROKR2 gene is known to have an important and not fully 
understood role in GnRH neurons migration, and mutations of this gene in humans can cause KS 
or nCHH syndromes with a phenotypic heterogeneity of reproductive and olfactory defects. 
Consequently we decided to focus the second part of this work on characterization of these 
variants in vitro and in vivo with the aim to better elucidate the role of prokineticin receptor 2 in 
CHH and GnRH neurons migration. PROKR2 GPCR signal transduction pathways functionality 
was studied in the above mentioned 4 novel and in other 4 already described variants that lack 
extensive functional studies (p.R47W, p.M64V, p.R85H, p.P290S). The functional study 
revealed that these missense allelic variants can affect protein targeting and signaling pathways 
with variable degree. In particular p.G70S, p.C208S and p.P290S are the more compromised 
10 
with a general impairment for both protein trafficking and Gs/Gq intracellular transduction 
pathways, while p.R47W, p.M64V and p.R85H variants are mainly affected in their targeting to 
the cell membrane, event thought with a still conserved activation. Interestingly, p.M278K and 
p.D99N variants showed a virtual lack of the Gs-pathway activation in the presence of a 
conserved response to the Gq-pathway stimulation. These findings indicate the need to evaluate 
the integrity of both PROKR2-dependent cAMP and IP intracellular accumulation for a more 
appropriate functional testing of novel identified allelic variants. 
The final part of this work was focused on generating an in vivo model for studying the role of 
PROKR2 in the migration of GnRH neurons using zebrafish animal model. Few data are 
available on literature about prokineticin receptors in zebrafish. Preliminary bioinformatics 
analysis revealed the presence of two well-conserved loci in the zebrafish genome, located on 
chr1, named prokr1a, and a predicted region on chr13 named prokr1b. To assess their expression 
during zebrafish development, we perfomed Real-Time qRT-PCR and whole mount In Situ 
Hybridization (WISH). For investigating the functional roles of prokr1a and prokr1b, 
knockdown experiments were performed injecting morpholino sequences. Downregulation of 
prokr1b, but not prokr1a affects the migration/architecture of GnRH3 neurons supporting the 
idea that prokr1b is the homologous gene of human PROKR2. To further analyze the impact of 
prokr1b on GnRH neurons migration, a ZF prokr1b knockout line was generated. Analysis of 
GnRH fibers network in zebrafish knockout line display the same migration defects observed 
during downregulation assay, confirming the role of prokr1b in the migrations of GnRH neurons. 
 
In conclusion, in the present work we applied a multidisciplinary approach to better elucidate the 
genetic and molecular mechanisms involved in CHH, focusing on the role of PROKR2 gene. 
Starting from genetic analysis we identified PROKR2 variants that were pharmacologically 
characterized by in vitro experiments to evaluate how these variants can affect signaling pathway 
or receptor membrane traslocation. Moreover, with expression and knockdown experiments, we 
identified the zebrafish PROKR2 human ortholog and generate a new in vivo model, that will be 
important in order to unravel the precise role of the prokineticin pathway in the pathogenesis of 
CHH.  
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Congenital Hypogonadotropic Hypogonadism 
The central control of sexual maturation and reproduction resides in a complex anatomical and 
functional network of hypothalamic neurons, converging onto, and regulating the activity of 
GnRH gonadotropic neurons. These neuronal circuitries impact on the development, maturation 
and activity of GnRH neurons and ultimately regulate critical aspects of sexual differentiation, 
puberty onset, gonadal function and fertility
2-4
. 
Congenital hypogonadotropic hypogonadism (CHH) is a disease with extremely variable 
phenotypic expression that affects the hypothalamic GnRH neuron, and includes two main 
groups of patients, those with olfactory defects (Kallmann syndrome, KS) and the normosmic 
patients with congenital hypogonadotropic hypogonadism (nCHH). The first case report came in 
1856 when Maestre de San Juan described an individual with absence of olfactory structures in 
the brain and presence of small testes
5
. Approximately a century after Franz Josef Kallmann 
identified the hereditary nature of this disease
6
 and Naftolin ascribed hypogonadism to a 
gonadotropin-releasing hormone (GnRH) deficiency
7
. CHH is more frequent in males (1:8000) 
than females (1:40000). Males frequently present with defective androgenization and growth at 
peripubertal age but micropenis and cryptorchidism may already be evident in the neonatal 
period, indicating a defective HPG activation during the prenatal development. Females 
generally present with primary amenorrhea and growth retardation. Additional neurological (e.g. 
anosmia, bimanual synkinesia, sensorineural hearing loss) and non-neurological defects (e.g. the 
midline or kidney defects, dental agenesis) may frequently co-exist and be linked to specific 
modes of inheritance. Biochemically, CHH patients present low or undetectable concentrations 
of circulating sex steroids and low/normal luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) serum levels, as a consequence of the impaired functionality of Hypothalamic-
Pituitary-Gonadal (HPG) axis due to the GnRH deficiency. 
 
The hypothalamic-pituitary-gonadal (HPG) axis 
The HPG axis plays a pivotal role in all vertebrates controlling many complex functions 
including growth, reproduction, osmoregulation, stress and metabolism. The physiological 
function of this axis is based on the pulsatile release of the GnRH by GnRH-neurons located in 
the hypothalamus. GnRH-neurons and olfactory system development are strictly connected; 
13 
during early stages of embryogenesis, GnRH-neurons arise outside of the brain in a niche at the 
border between respiratory epithelium and vomeronasal/olfactory from the neural crest and 
ectodermal progenitors. From these locations they start to migrate caudally in close association 
with developing sensory axons of the olfactory/vomeronasal/terminal nerve system to reach, 
passing through the cribriform plate, their final destination in the mediobasal hypothalamus
8
. 
Once in the hypothalamus, functional GnRH-neurons detach from the olfactory axonal guides, 
and complete their differentiation extending axonal processes to the medial eminence through 
which pulsatile GnRH is secreted into circulation via the hypophyseal portal system. The GnRH 
interacts with its specific receptor, the GnRH-R, which is expressed on the membrane surface of 
the gonadrope cells, thus stimulating the biosynthesis and secretion of the gonadotropins, 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The two gonadotropins are 
then transported through the peripheral circulation to the gonads, where they stimulate either the 
steroidogenesis (estrogen, progesterone, and androgens) or the gametogenesis (oocytes and 
spermatozoa). The gonadal steroids, in turn, auto-regulate their own secretion through a feedback 
mechanism at the hypothalamus-pituitary level, decreasing the GnRH and gonadotropin 
secretion
9
 (Figure 1). 
 
 
Figure 1: HPG axis illustration from Matzuk MM et al., Nat Med. 2008. 
 
The activity of the human GnRH-secreting neurons is present in the hypothalamus starting by the 
10
th
 week of gestational age, followed by the secretion of the two gonadotropins which are 
detectable from the 10
th
-13
th
 weeks of gestation when the hypophyseal portal system has 
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developed. The secretion of the GnRH, and then LH and FSH, decline at mid-gestation due to 
the negative feedback exerted at the hypothalamus and pituitary levels by the surge of the 
placental steroid. After the delivery, due to the lack of the placental steroid negative feedback, 
GnRH and the gonadotropins rise and remain elevated for the first 12-24 months in the girls and 
for the first 6 months in boys, identifying the so called “minipuberty”. Subsequently, due to 
inhibitory mechanism so far not fully understood and maybe involving the neurotransmitters g-
aminobutyric acid (GABA) and the neuropeptide Y (NPY) the GnRH, LH and FSH levels 
decrease and remain suppressed till the beginning of the pubertal development 
10,11
. Indeed, at 
puberty, the GnHR, and consequently the gonadotropins secretion resumes with a characteristic 
pulsatile manner, which is controlled by the GnRH pulse generator
9
. 
Therefore, the normal GnRH development and pulse generation processes are essential for the 
integrity of the HPG axis and, by consequence, for normal reproductive function. Studies 
conducted in last two decades underline how all these processes are under the control of several 
genes.  
 
Genetic of CHH 
a. Causal genes 
KS was originally described as caused by mutations in a specific X-chromosome gene, KAL-1
12
, 
with a consequent altered targeting of olfactory axons and migration of neurons producing 
GnRH, the key central regulator of the reproductive axis, but this genetic defect was soon found 
to be present in a minority of the patients. Thus, the causal event of the isolated CHH was often 
missing, and the classification of ‘‘idiopathic’’ CHH was consequently adopted. Nevertheless, 
the observation of familial cases with variable modes of inheritance (X-linked or autosomal 
dominant or recessive) soon indicated that CHH retains a highly heterogeneous genetic 
component. The application of conventional linkage studies to investigate the genetic basis has 
proven difficult, because most pedigrees tend to be of small size, since most patients remain 
infertile in the absence of therapeutic treatment. In the last decade, however, the knowledge on 
the pathogenesis of CHH has been profoundly deepened thanks to the utilization of animal and 
cellular models; these, together with the application of modern techniques of genetic 
investigation, brought evidence of previously unknown genetic determinants of CHH (either 
nCHH or KS). These new insights have played a significant role in disclosing the physiological 
15 
complexities of the HPG axis and therefore in elucidating the pathophysiology of CHH. 
Association with a multitude of candidate genes has nowadays been identified
13
. Some genes are 
determinant for the correct embryonic differentiation of the GnRH-secreting neurons or encode 
the signals essential for the correct migration of the GnRH neurons form their embryonic origin 
to the hypothalamus: the ANOS1/KAL-1; the receptor-ligand pair fibroblast growth factor 
receptor 1
14,15
 and fibroblast growth factor 8 
16,17
 (FGFR1/FGF8); the nasal embrionic LH 
releasing hormone factor (NELF)
18
; the heparan sulfate 6-O-sulfotransferase1 (HS6HST1)
19
; the 
ligand–receptor complex prokineticin 2 and its receptor (PROK2/PROKR2)20-24; the 
chromodomain helicase DNA binding protein 7 (CHD7)
25-29
; the class 3 and 7 semaphorins 
SEMA3A 
30-32
, SEMA3E
33
  and SEMA7A
32
; the Sry-related HMG box factor 10 (SOX10) 
34,35
; the 
WD repeat-containing protein 11 (WDR11) 
36,37
, the fibroblast growth factors 17 (FGF17)
38
, the 
interleukin-17 receptor D (IL17RD)
38
, the protein sprouty homolog 4 (SPRY4)
38
, the dual 
specificity phosphatase 6 (DUSP6)
38
, the FEZ family zinc finger 1 (FEZF1)
39
. Other genes 
encode the elements of upstream signals contributing to the activation of GnRH neuron, such as 
the two ligand–receptor couples formed either by the TAC3/TACR3 40-42 (tachykinin 3 and its 
receptor also named neurokinin B, NKB, and/or neurokinin 3 receptor, NK3) or the 
KISS1/KISS1R 
43,44,41
 (kisspeptin1 and its receptor, previously known as GPR54). Finally, 
candidate genes for CHH also include the GnRH gene itself (GnRH1)
45,46
 and its receptor 
(GNRHR) 
47,48
 (Figure 2). 
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Figure 2: On the left, genes involved in development and migration of GnRH neurons. On the right, genes 
responsible for GnRH neurons secretion and release of GnRH hormone (from Vezzoli V. et al., Minerva End. 2016).   
 
Thus, from KAL1 in 1991, the first gene associated with KS 
49,50
 more than 25 genes have been 
identified as involved in CHH, although not all of them are equally involved in the pathogenesis 
of the CHH. Indeed, we can consider some of them as major genes, due to their more frequent or 
important involvement in the molecular pathogenesis of CHH.  
 
ANOS1/KAL1: KAL1 gene, recently renamed ANOS1, is located in human on chromosome 
Xp22.3.  The 14 exons that constitute the gene encode for anosmin-1, a 100 kDa extracellular 
matrix glycoprotein of 680 amminoacids. This protein is composed by an N-terminal cysteine-
rich domain, followed by a whey acidic protein (WAP) domain, four fibronectin type III (FnIII) 
domains and a terminal histidine-rich region 
49,50
. The fibronectin type III domain is essential to 
create a flat surface with a strong basic charge, enabling interactions between anosmin-1 and 
other components of the extracellular matrix
51,52
(Figure 3).  
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Figure 3: Anosmin-1 structure (from Hu Y. et al., Trends Endocrinol Metab. 2010). 
 
Anosmin-1 in human was detected in the olfactory system from week 5 onward restricted to the 
olfactory bulb presumptive region and later, to the primitive olfactory bulbs. Fundamental 
insights into the pathology of X-linked KS came from the post-mortem examination of a male 
19-week-old human fetus carrying a chromosomal deletion encompassing the KAL1 gene. In this 
study, researchers reported that olfactory, vomeronasal and terminalis nerve fibers were not in 
contact with the brain neither were the GnRH neurons present in any area of the brain. 
Furthermore, they observed an abnormal accumulation of both nerve fibers and GnRH neurons 
in the upper nasal area, where they normally enter into the central nervous system
53
 (Figure 4). 
These findings indicated that the causative defect primarily affects the migration of early 
olfactory axons, which takes place from the beginning of week 5 onward
54
. Sequentially, the lack 
of contact between the olfactory axons and the forebrain during week 6 would in turn prevent 
olfactory bulb differentiation
55-57
. 
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Figure 4: GnRH3 migration failure in a male fetus mutated for KAL1; CP= cribiform plate; M= meninges (from 
Schwanzel-Fukuda et al., Nature 1989). 
Genetic studies of KS patients reported that KAL1 gene abnormalities include missense and 
nonsense mutations, splice site mutations, intragenic deletions and submicroscopic chromosomal 
deletions involving the entire KAL1 gene
58
. All, but one
59
, patients harboring KAL1 mutations are 
presenting olfactory dysfunction of variable extents, moreover they often have a more complex 
phenotype
60
 with a high incidence of  renal agenesis and bimanual synkinesia defects that occurs 
respectively in 30%–40% and 75% of the patients20. Analysis of familial cases of KS reported 
that KAL1 is mutated in approximately 60% of these patients, while only 10%–15% of males 
mutated for this gene present sporadic KS, suggesting an X-linked mode of inheritance
58
.  
FGFR1: FGFR1 gene, less frequently called KAL2, is located on chromosome 8p12. Its 
sequence contains 18 exons that translated generated a protein receptor belonging to the tyrosine 
kinase superfamily, that consists of four subtypes (named FGFR1–4) and seven FGFR isoforms. 
19 
These isoforms are able to specifically bind particular members of the 22 fibroblast growth factor 
(FGF) ligands. FGFR1 protein structure consists of three extracellular immunoglobulin-like 
loops (D1, D2 and D3), an acid box D1–D2 linker region that contains a stretch of negatively 
charged amino acids and a heparan sulphate-binding site, a transmembrane domain and an 
intracellular split tyrosine kinase domain
61
 (Figure 5). 
 
 
 
Figure 5: scheme representing structural domains of FGFR1. 
 
Alternative splicing in the second half of the juxtamembrane D3 domain could generate two 
transmembrane isoforms of FGFR1 protein termed IIIb and IIIc
62
. The FGF ligand binding 
region is formed by the terminal membrane domains of D2 and D3. While D3 isoform 
determines ligand-binding specificity, the D1 domain can act as a potential competitive auto-
inhibitor of the interaction between FGFR and FGF and HS folding back to interact with D2 in 
the FGF and heparan sulphate (HS) contact sites. FGFR1 signaling is based on dimerization and 
sub sequentially activation by autophosphorylation of receptor`s intracellular tyrosine kinase 
domains. These conformational changes in the receptor are inducted by the bindings of FGFs, 
heparin and HS proteoglycan  ligands 
63
. FGFR1 has been shown to play an essential role during 
embryogenesis, homeostasis and wound healing. Studies conducted during the development of 
central nervous system have underlined the critical role of FGF receptors and ligands in the 
20 
neurogenesis
64
. In the rostral forebrain, in particular FGFR and FGF affects the olfactory bulb 
development influencing, by consequence, the GnRH neuronal migratory activity
65
. In fact 
analysis of Fgfr1
-/-
 knockout (KO) mice have shown aplasia in the olfactory bulbs
65
. Moreover 
Fgfr1
-/-
 mice transfected with dominant negative FGFR1 mutations exhibited an early onset 
together with a 30% decrease of hypothalamic GnRH neurons
65
. These results suggested that 
loss-of-function mutations in FGFR1 result in a defect in GnRH neuron migration via the 
abnormal morphogenesis of the olfactory bulb, while specific gain-of function mutations in 
FGFR1 cause craniosynostosis
66
. Since the first reported association between FGFR1 loss-of 
function mutations and the dominant form of KS
67
, several FGFR1 mutations have been 
identified in KS-affected individuals and in patients with nCHH, all of them occurred in the 
FGFR1IIIc isoform and spanned all of the functional domains of the receptor
15,68
. Clinically 
features of CHH patients with FGFR1 defects includes, as for KAL1, also non-reproductive and 
non-olfactory disorders
60
. Nevertheless analysis of these cases revealed a wide phenotypic 
variability in unrelated probands and mixed pedigrees. As a matter of fact, patients from the 
same family that shared an identical mutation exhibited the coexistence of KS, isolated hyposmia 
without hypogonadism, and nCHH
15
. The presence of modified genes, the involvement of 
multiple genes or an epigenetic mechanism was proposed as explanations for such different 
phenotypic expression of the same genetic defects
69
. It is accordingly evident that the precise 
quantitative regulation of FGFR1 signaling is crucial for a normal development considering that 
both attenuated and increased signaling cause disparate phenotypes.  
 
HS6ST1: HS6ST1 gene is located on chromosome 2q21 and is composed by 2 exons. Its 
sequence encodes an enzyme of 411 amminoacids, whose function is to introduce a sulfate in the 
6-O-position of the glucosamine sugar moiety within heparan sulfate (HS) (Figure 6). 
 
Figure 6: Chemical structure of  HS. The red circle represents the sulfate residue introduced by HS6ST1 enzyme 
(from Tornberg J. et al., Proc Natl Acad Sci U S A. 2011) 
21 
HS polysaccharides are components of the extracellular matrix and are essential for neural 
development due to their control in cell-to-cell communications
70
. In particular, this post-
translational modification is important for the interaction and activation of the FGFR–FGF 
complex
63
 and for the interaction between anosmin1 and the cell membrane
64
. Bülow and 
collegues, in studies conducted using C. elegans model, demonstrated that overexpression of 
human KAL1 ortholog in specific worm interneurons causes axonal-branching defects
71
, and that 
this kal-1 gain-of-function phenotype is suppressed by HS 6-O-sulfotransferase gene (hst-6)
71,72
 
suggesting the role of HS6ST1 in the pathogenesis of nCHH/KS. Tornberg and coworkers 
support this thesis showing that all reported mutation founded sequencing the coding exons and 
flanking splice sites of the gene HS6ST1 in a cohort of 338 GnRH-deficient patients affects 
residues that are highly conserved in HS6ST1. Moreover, they found that HS6ST1 mutations 
recognized in patients with CHH reduce enzyme activity both in vitro and in in vivo
19
. Clinically, 
patients carrying HS6ST1 mutations could present a wide spectrum of severity of GnRH 
deficiency; this variability is also evident both within families that share the same genetic 
alteration
19
. Because HS6ST1 mutation associated with CHH has not been described in the 
homozygous state and segregates as a complex trait with inheritance patterns that likely resulted 
from oligogenic interactions, it was proposed that the identified HS6ST1 missense mutations 
might not be sufficient to cause disease, and suggested that HS6ST1 represents an important gene 
for the neuroendocrine control of human reproduction.  
 
KISS1/KISS1R: KISS1 gene is located on chromosome 1q32 and encodes for a 145-amino acid 
kisspeptin 1. This precursor is cleaved in four products: kisspeptin 54 or metastatin the longest 
54-amino acid peptide, and three minor products of 14, 13 and 10 residues called respectively 
kisspeptin 14, kisspeptin 13 and kisspeptin 10. All four peptides showed the same binding 
affinity and efficacy for receptor KISS1R; this leads to the hypothesis that the C terminal portion 
of the peptide is the important region for binding and activation of the receptor. KISS1R, 
previously known as GPR54, was mapped to chromosome 19p13.3. Translation of its sequence 
generates a 398 amino acids G protein-coupled receptor of 75KDa
73
. Expression analysis showed 
that while KISS1R is expressed in both the hypothalamus and pituitary, KISS1 is restricted to 
hypothalamus
73
. Studies conducted on Kiss1r knockout mice demonstrate that KISS1R affects 
the processing or release of GnRH, but not the migration of GnRH neurons
44,74
. These knockout 
22 
mice represent a phenocopy of Kiss1R
-/- 
human condition
44
, with normal GnRH neurons and 
hypothalamic content but almost absent sexual maturation. All mouse knockouts for Kiss1R and 
Kiss1 described in literature recapitulate the human nCHH phenotype, confirming the crucial 
role of ligand-receptor couple KISS1/KISS1R as proximal regulators of GnRH release 
75
. These 
findings support the role of KISS1 as a tiny regulator of puberty and HPG axis. Indeed, its 
increased expression have been proposed to be one of the effector mechanisms at puberty
76,77
 
while downregulation mediates the HPG suppression observed in severe nutritional 
deprivations
78
. Moreover, KISS1 neurons are highly responsive to estrogens, and were 
demonstrated to be implicated in both positive and negative central feedback of sex steroids to 
GnRH production
78
. The role of KISS1/KISS1R was supported by observations of GnRH 
deficiency and failure to initiate or progress through puberty in CHH patients, carrying mutations 
in these genes
79
. Inactivation of mutations in KISS1 and KISS1R shows an autosomal recessive 
pattern of inheritance.  
 
GNRH1: Gonadotropin-releasing hormone (GnRH), located on chromosome 8p21-11.2, is 
encoded by the GNRH1 gene. Composed by four exons and three introns,  GnRH1 sequence 
translation generates a 92 amino acids pre-pro-protein (pre-pro-GnRH), including: a 23 amino 
acids signal sequence followed by two serine residues, the GnRH decapeptide, a GKR sequence 
and GAP 6 GnRH-associated peptide, a 56-amino acid peptide
80
. It plays a crucial role in the 
HPG axis, regulating the reproductive physiology. In particular its synthesis by hypothalamic 
neurons and pulsatile secretion into the hypothalamic-hypophyseal portal circulation controls the 
synthesis and release of the two gonadotropins exercised by anterior pituitary in both sexes
80
. 
Gnrh1 KO mice exhibited anomalous tooth maturation and mineralization and a complete 
absence of GnRH synthesis that lead to infertility, sexually immaturity
80,81
. However, 
introduction of an intact GnRH gene into the genome of these mutant mice completely reversed 
the reproductive deficits
82
. Same was observed in humans where pulsatile GnRH administration 
reverted the delayed puberty phenotype in a male patient and his sister with homozygous 
mutation, affecting the peptide precursor pre-pro-GnRH
45
.  
 
GNRHR: GNRHR is the receptor of GNRH1; its sequence is mapped on chromosome 4q21.2 and 
generates a 328-amino acid GPCR of 60 KDa. Its structure consists of an extracellular 35-amino 
23 
acid amino-terminal domain, and seven transmembrane domains and does not present a carboxy-
terminal cytoplasmic tail
80
. Binding with its ligand, GnRH1 stimulates in the pituitary 
gonadotrope cells the beta isoform of Phosphoinositide phospholipase C, which mobilizes 
calcium and protein kinase, resulting ultimately in the activation of proteins involved in the 
synthesis and secretion of the gonadotropins LH and FSH. The GnRHR KO mouse model 
recapitulates clinical phenotype of CHH syndrome
83,84
, displaying reduced sexual organs, low 
gonadotropins and sex steroid levels, infertility, failure of sexual maturation and inability to 
respond to exogenous GnRH administration. Several human GNRHR loss of function mutations 
were described in CHH patients in the last 15 years
47
. Clinically, the phenotype of these 
individuals span a wide spectrum of defects ranging from fertile eunuch syndrome to the 
complete form of GnRH resistance, characterized by micropenis, cryptorchidism, very low 
gonadotropins levels and the absence of pubertal development. GNRHR mutations have been 
described in about 40–50% of familial nCHH cases, and in round 17% of sporadic nCHH85. 
 
TAC3/TAC3R: TACR3 or tachykinin receptors 3 gene is located on chromosome 4q25. It 
encodes for NK3R, a GPCR primarily expressed in the central nervous system that is activated 
when bound with its ligand Neurokinin B (NKB). NKB is a member of the tachykinin 
superfamily of neuropeptides, that also includes substance P and neurokinin A and is encoded by 
TAC3 gene, located on chromosome 12q13–q2186. Its expression analysis showed a wider 
distribution in the central nervous system, in particular it is expressed in the arcuate nucleus of 
hypothalamic neurons that project to GnRH secreting ones
86
. Despite the overlapping expression 
of neurokinin B and kisspeptin in the arcuate nucleus, and the fact that both are downregulated 
by estrogens, suggesting similar roles for both in relaying feedback from sex steroids to GnRH 
production, studies in animal models indicates different functions. Indeed, experiments 
conducted in various species underline different ability between KISS and NKB in the 
stimulation of release of GnRH. In particular, kisspeptin can stimulate GnRH release in almost 
all species, while NKB cannot. Moreover, observation of KO mice for NKB or KISS revealed 
distinct phenotypes, with NKB KO mice with a normal fertility, whereas KISS KO mice 
displayed a CHH classic phenotype
87-89
. Clinical studies on humans revealed an association 
between mutation of TACR3 and micropenis and cryptorchidism phenotypes in male patients, 
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demonstrating the importance of NKB/NK3R system for normal fetal gonadotrophin 
secretion
40,87
. 
 
PROK2 and PROKR2: PROK2 and PROKR2 are respectively ligand and receptors belonging to 
the family of prokineticins. This family is composed by two ligands PROK1 and PROK2 with 
similar affinities for their two receptors, namely PROKR1 and PROKR2. Receptors operate as 
molecular switches to relay extracellular ligand-activation to intracellular heterotrimeric G 
proteins, and present a high conservation in their sequence (about 85%). Meanwhile, whilst 
PROK1 and its receptor PROKR1 expressions are mainly confined to gastrointestinal system 
where they promote gut motility, PROK2 (locus 3p21.1) and PROKR2 (locus 20p13) present a 
more specific neuroendocrine profile
90,91
. Indeed they are located in the arcuate nucleus, 
olfactory track and suprachiasmatic nucleus. PROKR2, as a member of the GPCR family, has an 
extracellular amino-terminal end, an intracellular carboxy-terminal domain and a central core 
formed by seven transmembrane α-helical segments (TM1–TM7) 90(Figure 7).  
 
 
 
Figure 7: Structure of human PROKR2 (gently provided by Prof. G. Kleinau, Leibniz-Institut für Molekulare 
Pharmakologie, Berlin).  
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PROK2 gene encodes the protein Prokineticin 2, a peptide of 81 amino acids with pro-migratory 
activity that binds to its cognate G protein-coupled receptor (GPCR) PROKR2. Their molecular 
interaction activates the PROKR2 downstream signal cascade via Gq and Gs
92
. Prokineticins 
were demonstrated to be involved in several physiological functions in neurogenesis, regulation 
of circadian rhythms, metabolism, angiogenesis, pain perception, muscle contractility, 
hematopoiesis, immune response, thermoregulation and energy expenditure
93-96
. Alteration of 
this system was found to be associated with several pathological conditions, including 
cancer
97,98
, immunological response
99
, mood disorder (anxiety/depression)
100
, and 
cardiomyopathy
101
. Analysis of knockout mice models for both ligand and receptor revealed the 
role of PROK2 signaling in olfactory bulb (OB) morphogenesis and sexual maturation, 
suggesting PROK2 and PROKR2 as strong candidates for human GnRH deficiency
102,103
. Indeed, 
the homozygous Prokr2 null mouse model results in KS phenotype, while the heterozygous mice 
do not show any important reproductive abnormality. The involvement of the PROKR2/PROK2 
pathway in the pathogenesis of the CHH was first described in 2006
20
 and subsequently reported 
in several other patients series
104,105
. Pharmacologically, characterization of these variants 
demonstrate a variable impairment of their expression levels in heterologous cell system and a 
reduced activation of the Gq and Gs-dependent intracellular pathway
22,24,106
. Genetic analysis of 
PROKR2 variants showed that the majority of them were found in heterozygous state, suggesting 
an autosomal dominant mode of inheritance due to either haploinsufficiency or a dominant-
negative effect. Nevertheless, only the patients carrying homozygous mutations are displaying 
the most severe and penetrant clinical phenotypes
20,24,107
, while  patients with heterozygous 
mutations are presenting a variable expressivity or incomplete penetrance of both the 
reproductive and olfactory phenotypes. Moreover, very recently, PROKR2 variants, but not 
PROK2, have been also described in patients with combined pituitary hormone deficits
108,109
.  
Altogether, these data suggest an extensive role of PROKR2 in the control of the entire 
neuroendocrine system. Notwithstanding knowledge about the precise molecular mechanisms of 
PROKR2 in the neuroendocrine axis remains largely unexplored, underlying how further 
investigations are necessary.  
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b. Critical aspect in CHH phenomics and genomics 
Since the two form of the CHH, KS and nCHH, may exist in different relatives within unique 
familial settings, is supporting the idea that they may constitute variable phenotypic 
manifestations of largely common genetic defects. On such basis, a novel vision is now arising, 
in which CHH may be considered as a complex genetic disease characterized by variable 
expressivity, penetrance and modes of inheritance in which the inability to go through puberty 
represents the cardinal manifestation
110
. As in multifactorial complex diseases, the pathogenesis 
of CHH may include the influence of environmental factors, but also the concurrent involvement 
of SNPs or other genetic defects in two or multiple interacting genes. Indeed, the recent reports 
of patients carrying pathogenic rare variants in more than one gene have challenged the long-
held view of a strictly monogenic disorder. Oligogenicity, which is as frequent as the biallelic 
defects in a single gene, may partially account for the phenotypic variability of isolated GnRH 
deficiency, as demonstrated in a North-American cohort
69
.   
c. Open issues 
The genetic analysis of all the so far known causative genes allows to identify a genetic cause in 
~50% of the analyzed patients, letting half of them still “idiopathic”111. This implies that new 
strategic and methodological advances are needed to cover this gap. Moreover, the recent 
demonstration of the oligogenic pathogenesis of the disease open the question regarding how 
these genes are interacting between each other in determining the complex clinical phenotype. 
The use of specific animal models might be helpful in this respect. 
 
GnRH neurons in vertebrate models 
Comparative endocrinology studies about GnRH neuronal development conducted on vertebrate 
organisms in the last fifteen years has greatly contributed to the current knowledge of the human 
reproductive axis. These experiments identified twenty four distinct forms of GnRH across 
fishes, amphibians and reptiles underlying the presence of two to three GnRH paralogous forms 
in all vertebrate species
112-115
. Consensus nomenclature adopted in the last decades classified 
GnRH genes basing on location and functions in three main groups called GnRH1, GnRH2 and 
GnRH3
45,116-121
. GnRH1 neurons are found, in vertebrates, prevalently in the preoptic area 
(POA) and the caudal hypothalamus, where they exert hormonal control of reproduction via its 
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regulation of gonadotrophin secretion from the pituitary gland. For this reason they are also 
called hypophysiotropic-GnRH form
122
. GnRH2 and GnRH3 are respectively located in 
midbrain tegmentum and terminal nerve/nasal compartment and, while they are indicated as not 
hypophysiotropic, recent findings seem to suggest a indirectly “neuromodulatory” actions in 
reproductive neuroendocrine axis
122,123
.  Among vertebrates, teleost fish represent one of the 
most heterogeneous groups with three GnRH isoforms in seabass and two in zebrafish (ZF)
124
. 
Despite these differences, ZF, with its characteristic of optical embryos transparency and 
amenability to genetic manipulation and imaging, has proved to be an ideal model organism for 
studying the early migration of GnRH neurons and the formation of the GnRH network
125
.  
 
Zebrafish model system 
Zebrafish (Danio rerio) is a teleost fish native to Southeast Asia. Its unique combination of 
features makes zebrafish particularly well suited for experimental and genetic analysis of early 
vertebrate development. Zebrafish adults dimensions are tiny, thus many fishes can be housed in 
a small space. They have a relatively short generation time: an adult female reaches the sexual 
maturity in about three months, and it lays hundreds of eggs every few weeks per mating, 
generating a large progeny, suitable for genetic or experimental analysis. The fertilized embryos 
develop rapidly, making it possible to observe the entire course of early development in a short 
time. Somitogenesis begins at about 9 hpf (Hours Post-Fertilisation), at 24 hpf the zebrafish 
embryo has already formed all the major tissues and many organ precursors, such as a beating 
heart, circulating blood, nervous system, eyes and ears, all of which can be readily observed 
under a simple dissecting microscope. Larvae hatch by about 2.5 dpf (Days Post-Fertilisation) 
and they are swimming and feeding by 5–6 dpf126-128.  A variety of tools and methodologies have 
been developed to exploit the advantages of the zebrafish system. Zebrafish embryos and early 
larvae are optically clear, allowing for direct, non-invasive observation or experimental 
manipulation at all stages of their development, such as whole mount in situ hybridization 
analysis of gene expression patterns with extraordinarily high resolution
129
. The externally 
developing embryos are readily accessible to experimental manipulation by techniques such as 
microinjection of biologically active molecules (RNA, DNA or antisense oligonucleotides), cell 
transplantation, fate mapping and cell lineage tracing
130-133
. The genome editing techniques such 
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as TALENs and CRISPR/CAS9 implemented in the last few years have deeply revolutionized 
the applications of ZF model, circumventing some limitations of knockdown technique
134
.  
 
HPG axis in ZF  
HPG axis of ZF exhibits remarkable similarity to more evolved vertebrates, preserving the most 
important reproductive cells and hormones. In humans the triggering of HPG axis cascade of 
events begins in the hypothalamus by GnRH (gonadotropin releasing hormone) and kisspeptin 
(Kiss1) secreting neurons
135
. In non-mammalian vertebrates, such as teleosts, this process is 
conserved but in addition to kiss1, there exists a novel kiss2 gene
136-139
. Researches conducted on 
ZF demonstrated a different distribution of these two kisspeptin genes in the brain. Kiss1 
neurons are located in the ventral habenula, where they play a pivotal role in adaptive behaviors 
by regulating serotonergic and dopaminergic activities
140,141
, while Kiss2 fibers form a wide 
network projecting into the telencephalon, the mesencephalon, the hypothalamus and the 
pituitary where are directly in contact with GnRH3 neurons in the pars distalis
142
.  
Despite these slight differences, both in human and ZF species Kisspeptin and GnRH hormones 
produced by these two neuronal population are essential for the release and fine regulation of the 
follicle stimulating hormone FSH (also called GTH-I in ZF) and luteinizing hormone, LH (GTH-
II in ZF) by gonadotropic cells in the pituitary
143,144
. Indeed with a conserved mechanism kiss2 
ZF hormone act on GnRH3 neurons stimulating the secretion of GnRH hormone that is the main 
regulator of the puberty onset
137,145
. ZF gonadotropins GTH-I and GHT-II produced by 
gonadotropic cells in response to the stimulation of the GnRH
74,146-149
 mediate gametogenesis 
and steroidogenesis. In particular, FSH/GTH-I is responsible for spermatogenesis in male and 
folliculogenesis in female
150,151
 while LH/GTH-II stimulate steroidogenesis in male acting on the 
Leydig cell in the testis and in oocyte maturation and growth
149,152,153
 (Figure 8).  
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Figure 8: HPG axis in human (right) and zebrafish (left). In both organisms, Kiss neurons regulate, in the 
hypothalamus, GnRH neurons. In zebrafish there are two populations of Kiss neurons: kiss1 neurons (triangle in the 
figure) are localized in the habenular nucleus (Hb) while kiss2 (square) are more widely scattered in the 
hypothalamus (Hyp) and preoptic area (POA) (from Bonomi M. et al., Handbook of Models of Human aging ed. 2, 
in press). 
The analysis of GnRH-Gonadotrope-Vasculature architecture in ZF recently revealed a dual 
mode of gonadotropin regulation challenging the established model of delivery of GnRH3 
hormone in this fish
146
. 
Indeed in teleosts, a true median eminence has not been identified; instead, direct innervation of 
the endocrine cells (neuroglandular regulation) has been proposed as the predominant pathway 
by which the hypothalamus affects the gonadotropic cells
154-159
. Nevertheless using FSH:EGFP 
and LH:mCherry transgenic zebrafish line
152
 Golan and colleagues observed that GnRH3 fibers 
formed multiple boutons upon reaching the pituitary, but most of these structures were located in 
the neurohypophysis rather than adjacent to gonadotropes. These GnRH3 boutons are 
structurally similar to the GnRH varicosities found in the mammalian median eminence and are 
considered as the release sites of this peptide in mammals
160-163
 and in fish
164
. Moreover they 
found a close association between FSH cells and GnRH3 boutons, but only a fifth of the LH cells 
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were in contact with GnRH3 axons. These data suggest a more direct regulation of FSH cells 
rather than LH cells and a combination of neuroglandular and neurovascular delivery mode of 
GnRH3 hormone in ZF
146
.  
 
Hypophysiotropic form of GnRH in ZF 
In vitro and in vivo experiments revealed how hypophysiotropic neurons are dispersed in a loose 
continuum from olfactory region to hypothalamus. Zebrafish genome possesses only two form of 
GNRH (gnrh2 and gnrh3) missing GNRH1 mammalian orthologue gene. Expression of gnrh2 
gene is in midbrain tegmentum, identical to human counterpart, while for gnrh3 is more widely 
observed in forebrain areas of terminal nerve, ventral telencephalon, POA, and hypothalamus. 
This expression in POA and hypothalamus, like mammalian GNRH1, and the high homology 
with human GNRH1 (80%) suggest a role of gnrh3 in the regulation of gonadotropins release in 
zebrafish. This hypothesis was confirmed by its ability to increase the mRNA level of the 
luteinizing hormone beta (lhb) in cultured primary pituitary cells. Moreover injection of 
kisspeptin-10, a molecule implicated in the pulsatile secretion of GnRH, into the flathead 
minnow (a fish belonging to the cyprinid family, as zebrafish) increased gnrh3, but not gnrh2 
secretion. These evidences demonstrated that in cyprinid fish that have only two forms of gnrh, 
gnrh3 is the main hypophysiotropic form of GnRH
165
.  
 
GnRH3 neurogenesis in ZF 
The development of Tg(GnRH3:EGFP) transgenic line by Zohar group has allowed to study in 
details the embryonic origins of gnrh3 neurons and their structures during ZF embryogenesis. 
Using this ZF line they observed that the first fluorescent signal is detectable at 24 hpf in 
olfactory regions
118,166
. Axons elongation begins at 26 hpf where, from gnrh3 perikarya clusters 
located in olfactory placodes, projections begin to extend bilaterally dorsoventrally towards the 
pallium. This sprouting process continues in the following hours with some branches that arise 
from these axons and move dorsoventrally, whereas others caudoventrally. Between 32–36 hpf 
these projections meet caudally at midline to form the first commissure in the subpallium. New 
fibers arise from the somata around 40 hpf and elongate caudoventrally along the anterior and 
the optic commissures, to innervate the eyes. Concurrently a fourth set of axons starts its 
migration toward the hypothalamus. Later, at 48 hpf dorsocaudally axons end their route at the 
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midline forming a commissure in the pallium. Four distinct gnrh3 fibers tracts are notable at this 
developmental stage (48 hpf) in the brain: in the pallium, in the subpallium, along the optic tract 
to the eyes and in the direction of the hypothalamus (Figure 9). Outside of the brain, gnrh3 fibers 
were observed: in the retina, in the perikarya of the trigeminal ganglia and bilaterally along the 
spinal cord
123,166
. 
 
 
Figure 9: Schematic illustration of gnrh3 fibers at 48 hpf. Four structures are recognizable at this developmental 
stage: pallium commissure, anterior commissure, optic chiasm and bilateral prolungations that reach hypothalamus 
(Hyp) (from Bonomi M. et al., Handbook of Models of Human aging ed 2, in press). 
 
These data suggest a common embryonic origin for both olfactory bulb(OB)-terminal nerves 
(TN) and preoptic area (POA)–hypothalamic GnRH neuronal populations166. This hypothesis 
was supported also by the migration of gnrh3 somata, that consist of a bilateral stream of neurons 
moving from the olfactory region through the TN ganglion and ventral telencephalon to the 
ventral hypothalamus between 3 and 15 dpf. Indeed this migration path seems to use the 
preexisting vomeronasal-terminal nerves (VNN/TN) fibers as a scaffold, like mammals
118
. 
Finally, these results are reinforced by the evidence that laser ablation of the soma of gnrh3 
neurons in the nasal area during early development resulted in a complete lack of olfactory, 
terminal nerve, preoptic area, and hypothalamic gnrh3 neurons
167
. 
Recently, Zohar’s group generated a gnrh3-/- zebrafish line that harbors a deletion of 62 bp in the 
gnrh3 gene
168
. Surprisingly, aside from an increasing of mRNA levels of pituitary gonadotropin 
genes (fshb, lhb, and cga) only during initial development, no GnRH3 neurogenesis or 
reproductive defects were observed in such gnrh3 knockout line. Indeed, characterization of key 
components of the HPG axis downstream of gnrh3, performed in gnrh3
-/-
 ZF, indicates a normal 
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gametogenesis and reproductive performance for both sexes
168
. These results seems to be in 
contrast with previous experiment where gnrh3-expressing cells laser ablation in the early phase 
of zebrafish development (4–6 dpf) leads to infertility167, thus opening a discussion about GnRH 
established role as key reproduction regulator in all species of vertebrates, including zebrafish. 
Nevertheless authors propose, basing also on knockdown data published in the past
118,167
, that 
development and correct migration of the gnrh3 neurons remain fundamental to its appropriate 
function in ZF as it is demonstrated in humans. To explain the absence of phenotype observed in 
the gnrh3
-/- 
ZF model, they postulated that gene knockout could trigger a compensatory 
mechanism which is not activated by gene knockdown or cells ablation due to different timing or 
duration of the elimination
168
. 
 
ZF as a model to study CHH 
Zebrafish genome sequencing has demonstrated that zebrafish genome presents partial genome 
duplication. This is the consequence of a whole genome duplication event occurred during 
evolution in the ray-fin fish lineage, prior to the teleost radiation. After this divergence, the 
zebrafish genome has been resolving back to a diploid state again
169
. The result is that zebrafish 
could present two orthologues for the corresponding human gene. Despite this difference a 
genome analysis revealed that 71.4% of human genes has at least one zebrafish orthologue
170
. 
Moreover, 82% of human potential disease-related genes can be associated to at least one 
zebrafish orthologue, making zebrafish one of the most attractive and promising models for 
understanding the biological activity of human disease-related genes
170
. Due to these strong 
genome and anatomical conservations, ZF was used as a model for studying genes involved in 
CHH, such as KAL1 and KISS1/KISS1R. 
 
kal1a/kal1b.  Two orthologs of human KAL1 gene were identified in ZF genome called kal1a 
and kal1b. They present an homology in the amino acids sequences with human KAL1 of 75.5% 
and 66.5%, respectively. Both proteins shared the same domain structure with human anosmin-1 
that consist of: a cysteine-rich region at N-terminal followed by a whey acidic protein-like 
(WAP), four fibronectin type III domains, and a C-terminal histidine-rich region except for 
anosmin-1b(kal1b), where this last domain is missing
171
. In situ hybridization experiments 
revealed for kal1a trascript, a signal at 38 hpf in the olfactory bulbs, and a lower expression, in 
33 
midbrain, tectum, cerebellum, retina and spinal cord
171
. kal1b mRNA seems to be expressed at 
later developmental stages (from 48 hpf) in the olfactory epithelium, in the rostral telencephalic 
area, the cerebral lobes and pronephric ducts
171
.  Functional studies showed that downregulation 
of kal1a transcript impairs proper axon fasciculation of olfactory neurons, and their terminal 
targeting at the olfactory bulbs. On GnRH system, kal1a knockdown abolishes, in the 
hypothalamus, GnRH-immunoreactive cells, while for kal1b only a limited reduction in gnrh3 
neurons was observed
172
, suggesting a specific role for kal1a in the development of the 
endocrine GnRH system in zebrafish. 
 
kiss1/kiss2.  Studies conducted in ZF demonstrated that both kiss1 and kiss2 increase the number 
of GnRH3 neurons in zebrafish embryo. Patch clamp recording reveals that, while kiss1 
increases spike frequency and depolarizes membrane potential, kiss2 exercises the opposite 
effect suppressing spike frequency and hyperpolarizing membrane potential; this demonstrates a 
regulatory role of kiss1 on GnRH neurons
173
. 
 
 
 
 
 
34 
 
 
 
 
 
 
 
 
 
 
Aim of thesis 
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Aim of this PhD work was to apply a multidisciplinary approach to better elucidate the genetic 
and molecular mechanisms involved in CHH, focusing in particular on the role of PROKR2 
gene.  
For this purpose and thank to the availability in our laboratory of the largest Italian cohort of 
CHH patients (n=512), that was collected in collaboration with several Italian centers belonging 
to the “Società Italiana di Endocrinologia” (SIE), the “Società Italiana di Andrologia e Medicina 
della Sessualità” (SIAMS) and the “Società Italiana di Endocrinologia e Diabetologia Pediatrica” 
(SIEDP), we planned: 
1. to perform an extensive genetic screening of this cohort by applying the NGS technique 
available in our laboratory; 
2. to perform a pharmacological characterization of the PROKR2 gene allelic variants 
identified in the cohort, in order to evaluate their pathogenic impact on protein membrane 
translocation and on activation of the principal intracellular pathways; 
3. to generate an in vivo model of zebrafish, in order to investigate PROKR2 functions 
during GnRH neurons migration. 
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Materials and 
methods 
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Patients 
The largest biobank of Italian patients affected by CHH (n=512) was collected thanks to the 
“Network Italiano Ipogonadismo Centrale” (NICe) supported by: Società Italiana di 
Endocrinologia (SIE), Società Italiana di Andrologia e Medicina della Sessualità (SIAMS) and 
Società Italiana di Endocrinologia e Diabetologia Pediatrica (SIEDP). The institutional Ethic 
Committee approved the study and all patients gave their informed consent for the genetic 
investigations.  
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Genetic analysis 
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DNA Purification from whole blood 
Genomic DNA was extracted from 3 ml of blood obtained from CHH patients after adding 
EDTA according to Gentra® Puregene® Kit Qiagen®. DNA obtained was then diluited to a 
final concentration of 25 ng/µl and stored at -20°C. 
Next-Generation-Sequencing (N.G.S.) screening 
Genetic screening of genomic DNA samples obtained from CHH patients was performed using a 
multiplex-PCR approach (TruSeq Custom Amplicon, Illumina®). This technology represents the 
latest advancements to Illumina sequencing, aimed at optimizing data accuracy and research 
scalability. TruSeq Custom Amplicon (TSCA) is a fully customizable, amplicon-based assay for 
targeted resequencing. Typical sequencing workflow comprises: design of the panel of interested 
gene, sample/library preparation, cluster amplification, DNA sequencing, image analysis/base 
calling, read alignment, and variant discovery (Figure 10). 
 
Figure 10: Flowchart for TruSeq Custom Amplicon, Illumina®. (adapted from Illumina website, 
www.illumina.com). 
Design of the panel 
Panel of interested gene (KAL1, FGF8, FGFR1, TAC3, TAC3R, HS6ST1, GNRH, GNRHR, 
PROKR2, PROK2, KISS1, and KISS1R) was designed using Illumina DesignStudio® software 
(https://designstudio.illumina.com/). This software is a free interface for custom probe design, 
providing dynamic feedback to select desired amplicons. Amplicon designs are generated 
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automatically using an algorithm that considers a range of factors, such as GC content, sequence 
similarity, presence of repetitive sequences, and possible underlying variants (SNPs). Once 
design is complete, is it possible to view candidate amplicons covering regions of interest as well 
as their design scores. For our study the amplicons were designed to cover the entire coding 
sequences of the mentioned selected genes and 25bp upstream and downstream of each exon. 
Sample/Library Preparation 
According to Illumina TruSeq® DNA Sample Preparation Guide kit 250 ng of genomic DNA 
(gDNA) of each patient were used to prepare DNA library. 
 
 
Figure 11:  Flowchart for preparation of gDNA library. (adapted from Illumina website, www.illumina.com).  
 
a. Hybridization of oligonucleotides pools to gDNA 
During this passage a specific pools of oligonucleotides (CAT probes) hybridize to -
flanking regions of interest in unfragmented gDNA. 
b. Remove Unbound Oligos: 
This process removes unbound oligos from genomic DNA using a size-selection filter. 
Two wash steps using SW1 (Stringent Wash 1) ensure complete removal of unbound 
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oligos. A third wash step using UB1(Universal Buffer 1) removes residual SW1 and 
prepares samples for the next step. 
c. Extend and Ligate Bound Oligos: 
This process connects the hybridized upstream and downstream oligos. A DNA 
polymerase extends from the upstream oligo through the targeted region, followed by 
ligation to the 5' end of the downstream oligo using a DNA ligase. The result is the 
formation of products containing the targeted regions of interest flanked by sequences 
required for amplification. 
d. Amplify Libraries: 
This step amplifies the extension-ligation products and add index 1 (i7) adapters, index 2 
(i5) adapters, and sequences required for cluster formation. 
e. Clean Up Libraries: 
Uses of AMPure XP beads purify the PCR products from other reaction components. 
f. Normalize Libraries: 
This step normalizes the quantity of each library for balanced representation in pooled 
libraries. Only samples containing DNA require processing through the subsequent steps. 
g. Pool Libraries: 
Pooling libraries combines equal volumes of normalized libraries in a single tube. After 
pooling, dilute and denature the library pool before loading libraries for the sequencing 
run. 
Sequencing using MiSeq
®
 sequencer platform 
Sequencing was performed using Illumina MiSeq® sequencer platform. A single-use MiSeq 
Reagent Kit was used to perform sequencing run. Each MiSeq reagent kit includes a kit-specific 
flow cell type and Reagent Cartridge. The flow cell is a single-lane glass-based substrate on 
which clusters are generated and the sequencing reaction is performed (Figure 14 A). Reagent 
Cartridge is a single-use consumable consisting of foil-sealed reservoirs pre-filled with clustering 
and sequencing reagents sufficient for sequencing one flow cell (Figure 14 B).  
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       Figure 14: Illumina Flow cell©. B: Reagent Cartridge. 
Before being ready to be loaded in MiSeq® Reagent Cartridge DNA library need to be 
denaturated. 
Bioinformatic analysis 
Once completed the sequencing run, Illumina MySeq® generate a VCF (Variant Call Format) 
file.  This file contain all variant found for each patients filtered for Minor Alleles Frequency 
(MAF) inferior to 1%.  
Sanger Sequencing 
Variants identified through N.G.S. analysis have been confirmed by Sanger sequencing. This 
process consists of 4 steps: 
1. Amplification of interested gene by PCR; 
2. Electrophoresis on agarose gel of the amplified fragment; 
3. Purification of PCR product; 
4. Sequencing reaction;  
5. Analysis by automated DNA-sequencer   
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Amplification of the gene by PCR 
For each gene, the reaction mix was prepared by the following protocol: 
 
 
The amplification of the fragment was performed in a Thermal Cycler  
Electroforesis on agarose gel 
Each PCR product is checked on 3% agarose gel that separates DNA fragments between 100 
and 1000 base pair. Gels were prepared with TAE 1X buffer (0.04M Tris-acetate, 0.002M 
EDTA) and amended with the intercalating agent Midori Green (Bulldog Bio). Five μl of the 
sample were loaded and run onto the gel applying a 130mV voltage for around 30 minutes. 
In order to verify the presence of a PCR product, the gel is placed on an UV transilluminator 
that makes the bands visible; the molecular weight can be compared with molecular weight 
marker 100bp DNA Ladder (Euroclone).  
Purification of amplified fragment 
In order to purify enzymes, nucleotides and salts from the previous reaction, purification of 
the remaining volume of PCR is performed by Amersham Biosciences, GFXTM PCR – 
DNA and Gel Band Purification Kit. Purification protocol was performed as recommended 
by the manufacturer. 
Sequencing reaction 
Sanger sequencing is based on the selective incorporation of chain-terminating nucleotides 
by DNA polymerase during in vitro DNA replication. The sequencing reaction necessitates, a 
Template DNA  100 ng 
Buffer 5X  5.0 μl  
Primer Forward (10 pmol)  1.25 μl  
Primer Reverse (10 pmol)  1.25 μl  
dNTPs mix (10Mm each)  0.5 μl  
Go Taq Promega
TM
 (5U/μl)  0.25 μl  
DDW  Up to 25 μl  
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single strand DNA as template, one DNA primer, and Big Dye Terminator mix 3.1 ( Perkin 
Elmer) containing dNTPs, Amplitaq DNA Polimerase, MgCl2 and modified di-
deoxynucleotidetriphosphates (ddNTPs): these nucleotides that terminate DNA 
amplification, since lacking a 3'-OH group necessary for the formation of a phosphodiester 
bond between nucleotides; moreover, ddNTP are fluorescently labeled with different colours: 
Adenine: “HEK” green, Cytosine: “FAM” blue, Guanine: “NED” black and Thymine: 
“ROX” red. Amplitaq DNA Polimerase is characterized by two mutations, one in the active 
domain, that enables it to incorporate ddNTP in the DNA structure, and one in the N-
terminus domain, which eliminates 3’-5’ exonuclease activity. 
Sequencing reactions of gene fragments were performed with both sense and antisense 
primers, in order to sequence the full length of the fragments.  Then, sequence product is 
purified by ddNTPs and salts by  CENTRI-SEP Spin Columns (Princeton Separations). 
Analysis by automated DNA-sequencer 
The principle of sequencer is based on capillary electrophoresis, where DNA molecules of 
different size migrate in solution under the influence of an electric field. The shorter the 
fragments are, the fastest they are absorbed on the chromatographic column; then, they are 
hit by a laser that will excite the fluorescent molecule bound to the ddNTP, releasing a signal 
that will be detected by the analyzer according to the four different  colours. The analysis of 
the detected signals was done by the software ABI PRISM® 310 Genetic Analyzer (Perkin 
Elmer Applied Biosystem, Foster City, USA) and sequence analysis was performed by 
Sequencing Analysis Navigator (Perkin Elmer Applied Biosystem, Foster City, USA): the 
output is an electropherogram, a profile of peaks of different height and colour that identify 
the four DNA bases.  
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Creation of plasmids 
In order to perform functional studies, PROKR2 wild-type (wt) sequence was ordered by 
Missouri S&T cDNA Resource Center, USA and inserted in SPRT-pcDNA3 plasmid (Figure 
15). 
 
Figure 15: Schematic representation of SPRT-pcDNA3 vector. 
 
SPRT-pcDNA3 vector includes, at the 5’ end, a SPRT sequence which is translated in frame 
with the cloned protein at the N-terminal domain. This sequence includes a signal peptide (SP), 
for the secretion of the delivery of the protein to the citoplasmatic membrane, and a rhodopsin 
tag (RT), a 20-AA peptide derived from bovine rhodopsin.  
Mutagenesis PCR 
Plasmids containing the 8 variants of PROKR2 gene identified in our study by genetic analysis 
were generated by mutagenesis of SPRT-pcDNA3-PROKR2 plasmid. The mutant constructs 
were produced using QuickChange™ Site-Directed Mutagenesis Kit (Stratagene). Pfu Turbo® 
DNA polymerase, which has a high proofreading activity, amplifies both strands starting from 
synthetic oligonucleotides, of which one contains the mutation of interest (Table 1). Primer pairs 
were 40 bp and designed in order to have same Tm. 
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The sense primer carries the mutation at half of the total lenght, and can bind specifically to the 
target sequence. The antisense primer is always WT and has a 20 bp-overlap with the coupled 
sense primer. 
The PCR products were checked by loading on 1% agarose gel with 1μl Gel Loading 6X, and 
run applying a costant voltage of 130 Volt for 30’. Gel was then placed on a UV transilluminator 
and the interest band was identified by comparison with molecular weight 1kb DNA Ladder 
(Invitrogen). 
R47W  FW: GGATGAGGATGAGGACATGACCAAGACCTGGACCTTCTTC  
REV: GGTCTTGGTCATGTCCTCATCCTCACCATAGGGAGGTCAT  
M64V  FW: CGTCATTGGCATTGCACTGGCAGGCATCGTGCTGGTCTGC  
REV: GATGCCTGCCAGTGCAATGCCAATGACGATCTTGGCTGCG  
G70S  FW: GGCAGGCATCATGCTGGTCTGCGGCATCAGTAACTTTGTC  
REV: GATGCCGCAGACCAGCATGATGCCTGCCAGTGCAATGCCA  
R85H  FW: GCTGCCCTCACCCGCTATAAGAAGTTGCACAACCTCACCA  
REV: GCAACTTCTTATAGCGGGTGAGGGCAGCGATAAAGACAAA  
D99N  FW: TCTGCTCATTGCCAACCTGGCCATCTCCAACTTCCTGGTG  
REV: GAGATGGCCAGGTTGGCAATGAGCAGATTGGTGAGGTTG  
C208S  FW: TATTGTCAAGAGCCAGGAGAAGATCTTCAGTGGCCAGATC  
REV: GAAGATCTTCTCCTGGCTCTTGACAATAAAGAGGACCGTT  
M278K  FW: TGCCGCAGGAAGACGGTCCTGGTGCTCAAGTGCATTCTCA  
REV: TGAGCACCAGGACCGTCTTCCTGCGGCAGCGCAGCCGCTT  
P290S  FW: TCTCACGGCCTATGTGCTGTGCTGGGCATCCTTCTACGGT  
REV: TGCCCAGCACAGCACATAGGCCGTGAGAATGCACATGAGC  
Table 1: Primers used for mutagenesis of PROKR2. 
 
Enzimatic digestion with DpNI 
PCR products were then digested with Dpn I (New England Biolabs) which, binding methylated 
sequence Gm6ATC, degrades WT templates in the reaction (E. coli DNA is indeed methylated) 
and leaves neo-synthetized DNA that contain the mutation. 
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Seventeen μl of PCR products are digested for 2 hours at 37° C, with 10 units of Dpn I (1μl) and 
2μl of NEB 4 buffer (50mM Potassium acetate; 20mM Tris-acetate; 10mM Magnesium acetate; 
1mM DTT pH=7,9 at 25 °C) (New England Biolabs). 
Transformation of bacterial cells 
E. coli competent cells were transformed by One Shot® TOP10 (Invitrogen) as recommended by 
the manufacturer. 
PCR on colonies from plates 
6 colonies from selective LB agar plates were selected, grown in LB added with ampicillin 
50mg/ml for 5 hours at 37°C, at 170 rpm. Then, a PCR following the same protocol reported in 
“Amplification of the gene by PCR” using T7 and 741R primers indicated in Table 2. The clones 
were then verified by sequencing in order to verify that further mutations were not inserted by 
random mutagenesis in the DNA, as described in the section " Sequencing reaction”, while the 
primers used for the different reactions are the following: 
Primer T7  TAATACGACTCACTATAGGG  
247Fw  AAGTTGCGCAACCTCACC  
495Fw  AATTATCAAACGGCCTCC  
724Fw  TGCTATGCCAGGATCTCC  
741Rev  GGAGATCCTGGCATAGCA  
930Fw  TACCTCACTGCCTTCTACGTGG  
1130Rev  TTCAGCCTGATACAGTCC  
Table 2: primers used for the sub-cloning of PROKR2 gene. 
Maxiprep  
In order to obtain highest yield of plasmidic DNA (around hundreds of µg) of the selected clone, 
the DNA was extracted by PureYield
TM
 Plasmid Maxiprep System (Promega), following the 
manufacturer’s instructions. Plasmidic DNA was then quantified by spectrophotometer. 
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Cell colture 
For in vitro studies were used two cellular lines HEK 293 and COS7. HEK 293 is for Human 
embryonic kidney cells 293, a specific cell line originally derived from human embryonic kidney 
cells grown in tissue culture. COS (an abbreviation for CV-1 in Origin with SV40 genes) cells 
are a laboratory cell line derived in the 1960s from African Green Monkey, (Cercopithecus 
aethiops) kidney tissue. Both cells lines grow adherently to glass and plastic in culture and were 
maintained at 37 °C and 5% CO2  in a complete growth medium DMEM+GlutaMAX™-I 
(Dulbecco’s Modified Eagle’s Medium, Gibco) additioned with 10% FBS (fetal bovine serum,  
Gibco), 1% Pen:Strep and 1% Fungizone. 
Transfection Protocol 
Cells were transfected with FuGENE® HD transfection reagent (Promega) following the 
manufacturer’s instructions. The FuGENE® HD Transfection Reagent is a nonliposomal 
formulation designed to transfect DNA into a wide variety of cell lines with high efficiency and 
low toxicity. Following protocol is divided for COS7 and HEK293 cells and for FACS, Western 
Blot, Immunonfluorescence, Radioimmuno and Elisa assays. 
Day 1: 
 Plate 2*106   HEK 293 cells in 100mm Petri dishes; 
 Plate 2*106   COS7 cells were in 100mm Petri dishes; 
Day 2: 
 Split HEK 293 in a 6-well dishes seeding 2*105 cells/well for FACS analysis; 
 Split HEK 293 in a 6-well dishes seeding 2*105 cells/well for Western Blot analysis; 
 Split HEK 293 in a 96-well dishes seeding 2*105 cells/well for RIA analysis; 
 Split HEK 293 in a 96-well dishes seeding 2*104 cells/well for IP1-ELISA analysis; 
 Split COS7 in a 6-well dishes seeding 4*104 cells/well for Immunofluorescence analysis; 
Day 3: 
 Mix 93,5 μl DMEM+GlutaMAX™-I (Dulbecco’s Modified Eagle’s Medium, Gibco), 2,5 
μg of plasmidic DNA; 
 Add to the mix 4μl di FuGENE® and incubate for 15 minutes. 
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 Add 100 ul of the mix to cultured cells. 
Day 4: 
 Aspire cells medium; 
 Add 2 ml of new DMEM+GlutaMAX™-I (Dulbecco’s Modified Eagle’s Medium, 
Gibco) additioned with 10% FBS (fetal bovine serum, Gibco), 1% Pen:Strep and 1% 
Fungizone. 
Day 5: 
Functional study. Every experiment was conducted as a duplicate and repeated twice. Cells 
transfected with SPRT-pcDNA3 vector (empty vector) were used as negative control. 
 
Fluorescence-activated cell sorting (FACS) 
Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry. It provides a 
method for sorting a heterogeneous mixture of biological cells into two or more containers, one 
cell at a time, based upon the specific light scattering and fluorescent characteristics of each cell. 
It is a useful scientific instrument as it provides fast, objective and quantitative recording of 
fluorescent signals from individual cells. HEK 293 cells were transfected according to previous 
protocols and analyzed using FACScalibur™ Flow Cytometer - 3 Colors. Analysis was 
conducted on not-permealized HEK 293 using MAb anti-RT primary antibody gently provided 
by Dr. Sabine Costagliola (IRIBHM, ULB, Bruxelles, Belgium). 
 
Western Blot assay 
The Western Blot (sometimes called protein immunoblot) is a widely used analytical technique 
used in molecular biology, immunogenetics and other molecular biology disciplines to detect 
specific proteins in a sample of tissue homogenate or extract. Protein were extracted from HEK 
293 cells using RIPA buffer (10mM Tris-HCl pH 7.5, 500 mM NaCl, 0,1% SDS, 1% NP40, 1% 
sodium deoxycholate, 2 mM EDTA, 2 mM Na2VO4, 2 mM Na4P2O7, 2mM NaF). 
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Protein quantification 
For protein quantification we used Thermo Scientific™ Pierce™ BCA Protein Assay. A 
detergent-compatible formulation based on bicinchoninic acid (BCA) for the colorimetric 
detection and quantitation of total protein. This method combines the well-known reduction of 
Cu
+2
 to Cu
+1
 by protein in an alkaline medium (the biuret reaction) with the highly sensitive and 
selective colorimetric detection of the cuprous cation (Cu
+1
) using a unique reagent containing 
bicinchoninic acid. The purple-colored reaction product of this assay is formed by the chelation 
of two molecules of BCA with one cuprous ion. This water-soluble complex exhibits a strong 
absorbance at 562nm that is nearly linear with increasing protein concentrations over a broad 
working range (20-2000µg/mL). A standard curve was used to determine the protein 
concentration of each sample. 
Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE is a technique used in molecular biology to separate biological macromolecules, 
usually proteins according to their electrophoretic mobility. Mobility is a function of the length, 
conformation and charge of the molecule. A chemical denaturant (sodium dodecyl sulfate or 
SDS) is added to turn the molecule into an unstructured linear chain whose mobility depends 
only on its length and mass-to-charge ratio. In most proteins, the binding of SDS to the 
polypeptide chain imparts an even distribution of charge per unit mass, thereby resulting in a 
fractionation by approximate size during electrophoresis. 
For signal development we used Thermo Scientific™ Pierce™ ECL Plus Western Blotting 
Substrate, an highly sensitive, nonradioactive, enhanced acridan-based 
chemiluminescent/chemifluorescent substrate for the detection of horseradish peroxidase (HRP) 
on immunoblots. The reaction of the acridinium ester intermediates with peroxide produces a 
prolonged chemiluminescence, which can be visualized on X-ray film or an imaging system. 
 
Immunofluorescence assay 
Immunofluorescence (IF) technique uses the specificity of antibodies to their antigen to target 
fluorescent dyes to specific biomolecule targets within a cell, and therefore allows visualization 
of the distribution of the target molecule through the sample. Indirect IF uses two antibodies. The 
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primary antibody is unconjugated and a fluorophore-conjugated secondary antibody directed 
against the primary antibody is used for detection. 
COS7 cells were growth in 6-wells plates and transfected according to transfection protocols 
previous decribed. MAb anti-RT was used as primary antibody and Anti-Mouse IgG whole 
molecule–FITC produced in goat as secondary antibody. Pictures of microscope slides were 
taken using Nikon C2
+
®. 
 
Radioimmunoassay (RIA) 
Radioimmunoassay (RIA) is an in vitro assay that measures the presence of an antigen with very 
high sensitivity. Any biological substance for which a specific antibody exists can be measured 
at nanomolar and picomolar concentrations. The target antigen is labeled radioactively and 
bound to its specific antibodies (a limited and known amount of the specific antibody has to be 
added). Sample is then added in order to initiate a competitive reaction of the labeled antigens 
from the preparation, and the unlabeled antigens from the serum-sample, with the specific 
antibodies. The competition for the antibodies will release a certain amount of labeled antigen. 
This amount is proportional to the ratio of labeled to unlabeled antigen. A binding curve can then 
be generated which allows the amount of antigen to be derived.  For cAMP determinations, 
culture medium was removed 48 h after transfection and replaced by Krebs-Ringer-HEPES 
buffer for 30 min. Thereafter, cells were incubated for 60 min in fresh Krebs-Ringer-HEPES 
buffer supplemented with 25 M phosphodiesterase inhibitor Rolipram (Laboratory Logeais, 
Paris, France) and various concentrations of highly purified PROK2 10-7M(Fitzgerald Industries 
International). At the end of the 1-h incubation, the medium was discarded and replaced with 0.1 
M HCl. The cell extracts were dried in a vacuum concentrator, resuspended in water, and diluted 
appropriately for cAMP evaluations by RIA according to the method of Brooker et al. 
174
. 
Duplicate samples were assayed in all experiments. Results are expressed in picomoles of 
cAMP/ml. Concentration-effect curves were fitted with the Prism computer program (GraphPad 
Software, Inc.,San Diego, CA), and EC50 values were determined. 
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IP-One ELISA 
For this experiment we used Cisbio IP-One ELISA assay kit®.  This assay has been designed to 
monitor the activation of Phospholipase C (PLC) coupled receptors, which carry information 
within the cell. the activation triggers the release of D-myo-inositol 1,4,5 trisphosphate (IP3) 
resulting in a transient increase of intracellular Ca2+. The IP3 lifetime within the cell is very 
short (less than 30 sec) before it is transformed into IP2 and IP1. When LiCl is added to the 
culture medium, the degradation of IP1 into myo-inositol is inhibited, and IP1 can therefore 
accumulate in the cell. Then, after receptor activation, IP1 can be precisely quantified using the 
IP-One assay. 
Every experiment was conducted as a duplicate and repeated twice. For each well the OD 
(optical Density) at 620 nm were subtract from the OD at 450 nm. Average was calculated from 
duplicates of each standard, sample and NSB (nonspecific binding). 
Average net OD = Average bound OD – Average NSB OD 
Calculate % B/BO = divide the net OD for each standard and sample by standard CO net OD and 
multiply by 100 
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Maintenance of zebrafish 
Breeding fish were maintained at 28°C on a 14 hours light/10 hours dark cycle. They are bred in 
3-5 litre tanks in three different systems (Figure 16). Embryos were collected by natural 
spawning and staged according to what described by Kimmel and colleagues
126
. They are raised 
in an incubator at 28°C in fish water with 0,1% Methylene Blue in petri dishes. 
 
       Figure 16: ZebTEC Active Blue Stand Alone® system present in our lab (Tecniplast™).  
Stock solution for fish water: 34 g of Instant Ocean Sea Salt dissolved in 1 l of deionised H2O.  
Fish water: 50 ml of stock solution in 10 l of deionised H2O. 
 
We used the following zebrafish lines: 
wild type (wt):  
 AB strain: obtained from Wilson lab, University College London  
transgenic and knockout lines: 
 Tg:GnRH3-EGFP strain provided by Gothilf lab, Tel-Aviv University, Tel-Aviv 
 prokr1bct814/ct814 knockout strains provided by Prober lab, Caltech Institute, US-CA. 
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Real-Time qRT-PCR  
Real-Time qRT-PCR (Real-Time Quantitative Reverse Transcription PCR) is used for the 
detection and quantification of RNA targets. This technique use fluorescent reporter molecules 
(SYBR™ Green) to monitor the production of amplification products during each cycle of the 
PCR. Before the Real-Time PCR, this technique requires the extraction of RNA from tissues and 
then its retrotranscription in cDNA. 
Total RNA extraction  
Total RNA is extracted from embryos of different developmental stages using the 
TRIzol™(Thermo Fisher Scientific). Total RNA were extracted from pools of 20 embryos for 
each developmental stage using TRIzol™ Reagent and resuspended the in 20–50 µl of RNase-
free water, 0.1 mM EDTA, or 0.5% SDS solution. 
RT-PCR (Reverse Transcription-Polimerase Chain Reaction) 
The reaction was carried out following the protocol of SuperScript ® III First-Strand Synthesis 
System for RT-PCR (Invitrogen).  
Real-Time PCR 
Real-time analysis was performed using ABI PRISM™ 7900HT Fast Real-Time PCR System. 
For each developmental stage 50 ngr of cDNA were used. Elongation factor 1-alpha 1 (eEF1a1) 
gene was used as endogenous control. Quantification of the targets were normalized using the 
comparative CT method (also known as the ΔΔCT method), after ensuring that the targets and 
endogenous control had similar or relatively equivalent PCR efficiencies. Each experiment was 
conducted as a triplicate and repeated three times. 
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The following primers were used: 
prokr1a FW 5’ TTGTGCTTTGTGTCTCCATTAAC 3’ 
prokr1a REV 5’ TTATCCAGACCCCAAATATAAGC 3’ 
prokr1b FW 5’ AGGTTTTGTGCGCCTCAGTTAAT 3’ 
prokr1b REV 5’ CGACCCACACTCCTGTGATCAAA 3’ 
eef1a FW 5’ CTGGTGTCCTCAAGCCTGGTA 3’ 
eef1a REV 5’ ACTTGACCTCAGTGGTTACATTGG 3’ 
 
Synthesis of probes for In Situ Hybridisation (ISH) 
To perform an in situ hybridisation assay we synthesised two probes: a RNA antisense probe and 
a control RNA sense probe that is identical to endogenous transcript and consequently should not 
bind to the mRNA during the hybridisation, the last one is necessary to verify the specificity of 
the RNA–antisense probe. In order to synthesised the probes we designed two primers to amplify 
a 500 bp long sequence for GnRH3, prokr1a and prokr1b . Then we performed a RT-PCR 
reaction on total RNA extracted from 26 hpf (hours post fertilisation) embryos. 
The following primers were used: 
prokr1a FW 5’GGTACATGGCTATCGTTCACC 3’ 
prokr1a REV 5’CCTAACGCTCACAAAGCACA 3’ 
prokr1b FW 5’ATATGGCCATCGTTCATCCT 3’ 
prokr1b REV 5’CAGAACGATCCGCTTGAAGT 3’ 
GnRH3 FW 5’ AGCATGGAGTGGAAAGGAAG 3’ 
GnRH3 REV 5’ AGCCCATCTGTTCCTTCAGT 3’ 
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Cloning and transformation reaction 
The RT-PCR product was cloned in the pCR

II-TOPO
 
vector (Figure 17) following 
manufacturer’s instructions of TOPO TA Cloning kit (Invitrogen), that provide for the cloning 
of PCR product in the plasmidic vector and then its bacteric transformation using One Shot® 
TOP10 (Invitrogen) competent cells. pCR

II-TOPO
 
vector has two promoters Sp6 and T7 in 
order to synthesise the antisense and sense probes (Figure 17.). 
 
Figure 17: schematic representation of the pCR

II-TOPO
 
vector. (from TOPO® TA Cloning® Kit user manual 
Invitrogen). 
Isolation of plasmid DNA 
Recombinant colonies were screened and preparation of plasmid was performed using 
PureYeld
TM
 Plasmid Maxiprep System (Promega) according to the manufacturer’s instructions. 
The extracted plasmidic DNA was run on 1% agarose gel. The preparation was verified by DNA 
sequencing on both strands in order to understand the insert orientation and so to decide the 
restriction enzymes to linarise the plasmid in order to perfom the probes synthesis  
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Probes labelling and synthesis 
The linearized plasmids were then used as templates for antisense and sense digoxigenin-UTP 
labelling and for in vitro riboprobe synthesis following the DIG RNA Labeling Kit (SP6/T7; 
Roche) manufacturer’s instructions. 
RNA quantification 
Probes were run on 1% agarose gels and scanned using a Typhoon 9220 Imager (Amersham 
Pharmacia Biotech, UK) using Typhoon Scanner Control Software (release 2.0). Densitometric 
quantitation of the bands was performed using Windows ImageQuant 5.1 Software. 
 
Whole mount In Situ Hybridisation (WISH) 
Embryos at the appropriate stage were fixed in 4% paraformaldehyde (PFA)/ phosphate buffered 
saline (PBS) over night at 4°C; then they were dechorionated and the embryos were dehydrated 
in 100% methanol and stored at -20°C until processed for whole mount in situ hybridisation as 
described by Jowett and collegues
175
. 
 
Loss of function analysis 
We tested two different antisense morpholino oligonucleotides (MOs) for both prork1a and 
prokr1b. All of them were splice-blocking MO synthesised by Gene Tools LLC (Oregon, USA). 
The morpholino sequences are the following: 
prokr1aSPL1:    5’    ATTTAAGACAAGCACTCACCTGTCC    3’ 
which corresponds to the putative exon 1/ intron 1 boundary of zebrafish prokr1a; 
prokr1aSPL2:    5’    TGTACCTGTTGAATACAGAACGTGA    3’ 
which targets the putative intron 1/exon 2 boundary of zebrafish prokr1a; 
prokr1bSPL1:    5’ AGTATGTAAATCCCACTGACCTGTC     3’ 
which corresponds to the putative exon 1/ intron 1 boundary of zebrafish prokr1b; 
60 
prokr1bSPL2:    5’  TATACCTGAACACAGAGACCACAGT     3’ 
which corresponds to the putative intron 1/exon 2 boundary of zebrafish prokr1b; 
Morpholinos were dissolved in Danieau’s solution (58 mM NaCl; 0,7 mM KCl; 0,4 mM 
MgSO4
.
H2O; 0,6 mM Ca(NO3)2; 5 mM Hepes pH 7.2) at 2 mM concentration and stored at –
80°C.  
Embryos were microinjected at the 1–4 cells stage and Rodamin dextran (Molecular Probes) was 
usually co-injected as a tracer. As a negative control we injected standard control morpholino 
(ctrl-MO) that targets human β-globin gene. This oligo has not been reported to have other 
targets or generate any phenotypes in any known test system except human β-thalessemic 
hematopoetic cells. 
Ctrl-MO:    5’    CCTCTTACCTCAGTTACAATTTATA    3’ 
About 40 embryos are aligned on the edge of a slide that is placed in a 100 mm petri dish. The 
microinjections were performed by the “Micromanipulator 5171” (Eppendorf) and the 
microinjector “Cell Tram Oil” (Figure 18).  
 
 
    Figure 18: microinjection equipment. 
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After injection embryos were raised in fish water at 28ºC and observed up to the stage of interest.  
Imaged embryos after 24 hpf were treated with PTU 1X (1-Phenil-2-thiourea, SIGMA; stock 
PTU 10X 0.015 g of PTU powder in 50 ml of fish water) to inhibit pigment formation 
(Westerfield, 1995). For a better observation the injected embryos are anaesthetized using 
tricaine 1X (Ethyl 3-aminobenzoate methanesulfonate salt, SIGMA; stock tricaine 25X 0.08 g in 
20 ml of distilled H2O) in fish water and PTU 1X. Injected embryos (morphants) were embedded 
at 48 hpf in UltraPure™ Low Melting Point Agarose (Thermo Fisher Scientific) and 
photographed using confocal laser scanning microscope Nikon C2
+
® with 20X lens. 
 
Generation of Tg:GnRH3-EGFP/prokr1b
ct814/ct814 
line 
To generate Tg:GnRH3-EGFP/prokr1b
ct814/ct814 
line we crossed Tg:GnRH3-EGFP line with 
prokr1b
ct814/ct814 
fish obtaining Tg:GnRH3-EGFP/prokr1b
ct814/wt 
line. Fish generated by this 
mating (F1 generation) were raised, screened at 24 hpf for EGFP and incrossed generating F2 
generation. Fin clipping were performed in order to isolate genetic material from individual fish 
for the purpose of genotyping.  A small amount of tissue is clipped from the end of the tail in 
order to extract DNA which will be used for further analysis such as PCR. 
Procedure: 
 Fish were anesthetized by immersion in 0.02% MS-222 (tricaine) at neutral pH until gill 
movement is slowed.  Stock preparation is 4g/L buffered to pH 7 in sodium bicarbonate 
(at 2:1 bicarb to MS-222). The dosage for adult anesthesia is 168ug/ml or 4.2ml stock 
solution in 100 ml water. The anesthetized fish is then transferred immediately onto a 
petri dish or clean surface using a plastic spoon.   The fin is clipped with a razor blade, 
surgical scissors or scalpel at a point not greater than halfway between the tip of the fin 
and the point where the scales end.  No more than 50% of the fin area were removed.  
 Fish are then immediately transferred to a container with fresh system water and 
monitored continuously until they are recovered and the ability to right themselves.  
 Tissue removed were put in a labeled 1.5 ml Eppendorf containing 50 µl lysis buffer (10 
mM Tris pH 8, 2 mM EDTA, 0.2% Triton X-100, 200 µg/ml Proteinase K). 
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 Samples were put at 55 °C overnight. 
 To inactivate proteinase K sample were heated at 95 °C for 15 minutes. 
Genomic DNA was used as template for PCR. 
 prokr1b
ct814/ct814 
fish contains a 1 bp deletion  (nucleotide 12 of the open reading frame: 5’- 
C-3’), which results in a change in reading frame after amino acid 4 and a premature stop 
codon  after amino acid 13 compared to 396 amino acids for the WT protein. 
Primer used for genotyping are the following: 
prokr1bGen FW 5’ TGAGCGTAATGCTAATGGTCT 3’ 
prokr1bGen REV 5’CCAGAGTGGCGATAAACACA 3’ 
 
PCR products were purified and sequenced in the same way described in Sanger sequencing 
section to identify Tg:GnRH3-EGFP/prokr1b
ct814/ct814
 fish. 
At 48 hpf fish were embedded in UltraPure™ Low Melting Point Agarose (Thermo Fisher 
Scientific) and photographed using confocal laser scanning microscope Leica TCS SP8® with 
20X and 40X lens. 
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Genetic analysis  
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CHH patients cohort composition 
Genetic analysis was performed on a cohort of 512 CHH patients composed by 38% affected by 
Kallmann Syndrome (KS) and 62%  normosmic CHH. For KS patients, 24% were female and 
76% male, while for nCHH 75% male and 25% female (Figure 19). 
 
 
Figure 19: Chart A represent KS and nCHH patients composition of CHH cohort analyzed while B and C represents 
sex imbalance for single pathologies.  
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Genetic analysis of CHH variants 
Genetic analysis revealed the presence of variants in 32.2% of patients. A total of 204 variants 
were identified in our cohort, the majority of them (140) were missense variants (Table 3).  
 
 
Table 3: genetic variants identified in CHH cohort divided for type of mutations. 
 
 
Analysis of variants displayed that 23.8% were monoallelic, 3.8% biallelic and 4.6% were 
digenic (Figure 20). 
 
 
 
Figure 20: Chart representing variants distribution among CHH cohort. No variants: patients with no mutation on 
analyzed genes; monoallelic: patients carrying variants on one allele; biallelic: patients with mutation on both alleles 
of a single gene; digenic: patients carrying mutation on more than one gene.  
 
Variants distribution among genes showed that FGFR1, PROKR2, GNRHR, KAL1 and TACR3 
genes resulted the most mutated in our cohort with 12.5%, 7.5%, 6.3%. 5.6% and 4.8% of 
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patients carrying rare variants, respectively. No mutations were founded in HS6ST1 gene (Figure 
21). 
 
 
 
Figure 21: Chart representing variants distribution among genes analyzed. 
 
 
PROKR2 variants 
Genetic screening of PROKR2 gene in our CHH cohort allowed the identification of 17 variants 
in 35 patients. 15 variants were missense and 2 frameshift mutations; these two led to premature 
stop codon. Moreover, we found only one variant in homozygous state (p.R85H) in a KS and in a 
nCHH patients, whereas the majority were found in heterozygous state (Table 4).   
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Variants rs/CM M.A.F. Bibliography Ref. 
p.R47W rs768088473 N/A N/A 
p.M64V CM111638 N/A Sykiotis (2010) Proc. Natl. Acad. Sci.  
p.G70S** rs764674615 N/A N/A 
p.R85H rs74315418 MAF< 0.01 Dodé (2006) PLoS Genet;  
Abreu (2012) Mol Endocrinol.; 
Caronia (2011) N. Engl. J. Med.; 
p.V158I rs368732206 0.0002  
(ExAC) 
Sarfati (2013) Eur. J. Endocrinol.;  
Libri (2013) J. Clin, Endocrinol. 
Metab.;  
p.L173R rs74315416 MAF=0.004 Dodé (2006) PLoS Genet.;  
Avbelj Stefanija (2012) Hum. Mol. 
Genet.; 
p.C208S** N/A N/A N/A 
p.R268C rs78861628 MAF: 0.01 Dodé (2006) PLoS Genet; 
1000 Genomes Project (2010) Nature;  
Berg (2013) Genet. Med.;  
p.M278K** N/A N/A N/A 
p.P290S rs149992595 0.0001071 
 (ExAC) 
Dodé (2006) PLoS. Genet. ;  
Miraoui (2013) Am. J. Hum. Genet. ; 
Monnier (2009) Hum. Mol. Genet. ; 
p.D99N** rs773364376 N/A N/A 
p.T260M rs370738961 0.00006  
(ExAC) 
Sykiotis (2010) Proc Natl Acad Sci 
USA; Libri (2013) J Clin Endocrinol.; 
p.V331M rs117106081 MAF: 0.012 Dodé (2006) PLoS Genet.;  
1000 Genomes Project (2010) Nature ; 
Berg (2013) Genet. Med.;  
p.V334M rs371564610 0.00002  
(ExAC) 
Sarfati (2013) Eur. J. Endocrinol.;  
Libri (2013) J. Clin. Endocrinol. ; 
p.R357W rs375036628 N/A Cole (2008) J. Clin. Endocrinol. ; 
Miraoui (2013) Am. J. Hum. Genet. ;  
Sbai (2014) FASEB J. ; 
p.H20MfsTer24 
(c.58delC) 
rs587777834 N/A Dodé (2006) PLoS Genet. ;  
Libri (2013) J. Clin. Endocrinol. ;  
Miraoui (2013) Am. J. Hum. Genet. ; 
p.N15TfsX30 
(c.43_44insCTTTA) 
rs776060323 N/A Libri (2013) J. Clin. Endocrinol. Metab.  
 
Table 4: PROKR2 variants identified in KS and nCHH populations. ** indicated novel identified variants. 
 
Pharmacological studies of some of these PROKR2 variants (p.V158I, p.V334M, p.N15TfsX30) 
were previously performed in our lab (Libri DV et al, 2013). Thus, in the present thesis, we 
focused on four novel PROKR2 variants (p.G70S, p.D99N, p.C208S and p.M278K) and four 
previously reported variants (p.R47W, p.M64V, p.R85H and p.P290S) that were identified in our 
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CHH cohort. All these PROKR2 variants were characterized by specific in vitro studies. An 
analysis of selected variants using the most known in silico software to predict potential effect of 
sequence alterations, revealed that p.R47W and p.M64V are the more tolerated, while for the 
majority of software the other variants are considered as disease-causing (Table 5). 
 
 
 
Table 5: disease causing prediction analysis using SIFT, PROVEAN POLYPHEN and MUTATION TASTER 
software. 
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PROKR2 in vitro studies 
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To characterize the selected PROKR2 variants identified in our cohort we cloned them and wild-
type PROKR2 sequence into SPRT-pcDNA3 plasmid (see Materials and Methods). The presence 
of a rhodopsin tag at N-Terminal of all the engineered plasmids allowed us to detect and measure 
protein levels in FACS assay and Western Blot, by using a specific antibody against this 
rhodopsin Tag (kindly provided by Dr.Sabine Costagliola, IRIBHM, ULB, Bruxelles). 
 
Fluorescence-activated cell sorting (FACS) 
FACS assay were conducted on non- permeabilized HEK 293T cells to measure the amount of 
receptor expressed on the cell membrane. 
 
Figure 22: Chart representing the expression of PROKR2 receptor variants on HEK293T not-permeabilized cells. 
All value were calculated as fold of PROKR2 WT. ***= P<0,001 (One-way-ANOVA). 
 
Results display a statistically significant reduced expression of the prokineticin receptor on the 
membrane for all variants (Figure 22). In particular, p.R47W, p.M64V, p.D99N and p.R85H 
variants display a moderate reduction (from 30% to 50%) in respect to PROKR2 WT, while the 
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remaining variants (p.G70S, p.C208S and p.P290S) expressed really low levels of the receptors 
on cell membrane (Table 6). 
 
Variant Expression: 
(fold of wt) 
Variant Expression:  
(fold of wt) 
PROKR2 WT 1,00 D99N 0,321 
R47W 0,490 C208S 0,103 
M64V 0,352 M278K 0,170 
G70S 0,085 P290S 0,058 
R85H 0,545 pcDNA3 0,014 
 
Table  6: Recapitulatory expression of PROKR2 variants revealed by FACS analysis. All numbers were expressed 
as fold of PROKR2 WT 
 
Western Blot 
To better assess expression of PROKR2 variants we performed a Western Blot assay on total 
lysates from HEK 293T transfected cells. Densitometric analysis showed that monomeric form 
of PROKR2 is expressed at comparable levels for all the variants (Figure 23).  
 
Figure 23: Western Blot of PROKR2 WT and variants. On the bottom, Actin levels were measured and used to 
normalize PROKR2 monomeric protein levels. 
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Interestingly, our antibody detected for all samples a different specific signal at higher molecular 
weight than PROKR2 monomer (72-95KDa). In a recent work, it was proposed that PROKR2 
exists as a dimer in vivo
176
 thus, basing on this paper, we hypothesized that the protein giving 
this signal could be the dimeric form of PROKR2. A subsequent densitometric analysis of this 
signal revealed low intensity levels for p.G70S and p.C208S (Figure 24 B).  
 
 
Figure 24: Expressions levels of PROKR2 monomeric and dimeric form. A: monomers are similar to wild type; B: 
supposed PROKR2 dimeric form signal. Both data sets were normalized on respective wild-type level. 
***=P<0,001(One-way-ANOVA). 
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Immunofluorescent assay 
To evaluate intracellular localization of the proteins generated by PROKR2 variants, we 
performed a immufluorescence assay on permeabilized COS7 cells fixed at 48 hours post-
transfection. 
 
 
Figure 25: Immunofluorescence conducted on permeabilized COS7 cells. Green signal represent PROKR2 , blue 
are cellular nucleus colored with DAPI. 
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Observing the distribution of PROKR2 signals is possible to note how p.G70S, p.C208S, 
p.M278K and p.P290S variants present strong intracellular signals compared to WT protein 
(Figure 25), suggesting a difficult receptor membrane-trafficking of these PROKR2 variants. 
 
Functional studies 
To assess the impact of our variants on intracellular signaling pathways of PROKR2, HEK293T 
cells were transfected with pcDNA3/SPRT-PROKR2-variants plasmids and stimulated with 
increasing doses of human PROK2 ligand. The PROKR2 is coupled either to the Gs-dependent 
or the Gq-dependent signaling pathways, and, as we firstly demonstrated
24
, it is important to 
evaluate both during the characterization of the PROKR2 allelic variants. Thus,  either the levels 
of cAMP and IP1 (a metabolite of PIP2-calcium pathway) were measured for all the tested 
variants. 
Gs-dependent signaling pathway 
 
Figure 26: Chart on the left represents values of cAMP measured in HEK293T cells transfected with PROKR2 
variants after stimulation with PROK2 ligand. Table on the right displays the Emax  (as percentage of PROKR2 
WT) and EC50 calculated using GraphPad Prism 5
©
.  
 
Cells lysate were collected, and intracellular cAMP levels were measured using 
radioimmunoassay (RIA) technique. Concentration-effect curves were constructed using 
GraphPad Prism 5
©
.  
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Analysis of chart and table reported underline how PROKR2 variants could be arbitrary divided 
for their functionality in three groups (Figure 26) :  
- p.R47W, p.M64V and p.R85H showed a reduction of their Emax to about 50% of 
PROKR2 WT.  
- p.D99N showed a strong reduction of the Emax of around 15% of the WT. 
- p.G70S, p.C208S, p.M278K and p.P290S present a virtual absent response in terms of 
cAMP accumulation.  
All active variants present EC50 values comparable with the PROKR2 WT. 
Gq-dependent signaling pathway 
 
Figure 27: Chart and table show IP1 levels of PROKR2 WT and variants. Emax  (as percentage of PROKR2 wild-
type) and EC50 were calculated using GraphPad Prism 5
©
. 
 
Gq-pathway activity was estimated using IP-One ELISA assay kit CISBIO
©
. Intracellular IP1 
accumulation was measured after stimulation with increasing doses of PROK2 ligand. Similarly 
to Gs-pathway analysis, it is possible to divide PROKR2 variants in three groups based on the 
levels of the Emax they achieved. The p.R85H variant showed a pharmacological profile 
comparable to PROKR2 WT, while p.M278K, p.R47W, p.M64V and p.D99N variants present 
about a 40% reduction of their Emax compared to WT receptor. Variants p.G70S, p.C208S and 
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p.P290S showed the strongest reduction of their IP1 Emax, between 60 and 75% of the WT 
(Figure 27).  
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PROKR2 in vivo analysis  
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Bioinformatic analysis 
Bioinformatics analysis conducted aligning human PROKR2 nucleotide sequence with ZF 
genome using Blastn™ alignment revealed the presence of two possible homologous sequence 
inside the zebrafish genome localized on Chr.1 and Chr. 13 respectively named prokr1a 
(NM_001173406.1) and prokr1b (NM_001173407).  
Alignment of protein sequences of Prokr1a and Prokr1b with human PROKR2 revealed a high 
degree of similarity (Figure 28) 
 
 
Figure 28: Similarity is a score of how similar each amino acid (or groups of amino acids) is across the whole 
alignment. 
 
The identity percentage of the two ZF protein sequences compared to human PROKR2 is about 
70% for both with Prokr1b that displays a slightly higher value (77,3%) in respect to Prokr1a 
(72,3%) (Figure 29). 
 
Figure 29: Alignment of protein sequences of Prokr1a, Prokr1b and PROKR2. 
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Synteny analysis performed using Genomicus web server 
(http://www.genomicus.biologie.ens.fr/genomicus) revealed a good conservation of blocks of 
genes between mammals’ chromosomes, but no shared synteny between mammal and fish 
(Figure 30).  
 
 
 
Figure 30: synteny describes the physical co-localization of genetic loci on the same chromosome within an 
individual or species. 
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Real-Time qRT-PCR 
To evaluate expression of prokr1a and prokr1b during early developmental stages of ZF, we 
performed Real-Time qRT-PCR on RNA extracted from ZF embryos.  
 
 
Figure 31: Real-Time qRT-PCR analysis displaying the expression levels of prokr1a (A) and prokr1b (B). Figure C 
is a representation of the migration pattern of GnRH (adapted from Palevitch O. , et al,  Dev Dyn. 2009).  
***=P<0,001(One-way-ANOVA). 
 
Results displayed that prokr1b (Figure 31 B) has higher expression level compared to prokr1a 
(Figure 31 A). More  interestingly, expression of prokr1b start to increase at 24 hours post 
fertilization (hpf) until 72 hpf, seeming to be consistent with the migration pattern of GnRH3 
fibers described in literature
166
  (Figure 31 C). 
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Whole-mount In Situ Hybridization 
To characterize the spatial expression a whole mount In Situ Hybridization (WISH) were 
conducted on fixed embryos at differents developmental stages. 
Results revealed for prokr1b a signal in the olfactory placode (OP) from 36 hpf to 72 hpf (Figure 
32 B1-B6) that is comparable to the GnRH3 signal (Figure 32 C1-C6). Otherwise, prokr1a 
displays only a feeble signal in midbrain-hindbrain junction at 36 hpf and 48 hpf (Figure 32 A1-
A4) and later at 72 hpf in the liver (Figure 32 A5-A6). 
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Knockdown experiments 
To further characterize the role of prokr1a and prokr1b gene in the migration of GnRH3 neurons 
along ZF development, we perfomed knockdown experiments. 
Two morpholino sequences for prokr1a and prokr1b were designed and ordered on Gene Tools 
LLC website (http://www.gene-tools.com/). Sequences were tested injecting different doses of 
each morpholino sequences in ZF embryos at one-cell stage. Total RNA was extracted from 
injected embryos at 24 hpf, retrotranscribed and a RT-PCR were performed to assess the 
specificity of morpholino sequences (Figure 33).  
 
 
Figure 33: RT-PCR on uninjected and injected embryos. Red arrows indicate morpholino sequences able to 
downregulate their target gene. 
 
As showed in the figure above, prokr1aSPL1 and prokr1bSPL2 downregulate specifically 
expression only of prok1a and prokr1b respectively. 
Knockdown effect of prokr1a and prokr1b genes were evaluated taking advantage of 
Tg:GnRH3-EGFP ZF transgenic line (gently provided by prof. Yoav Gothilf, Tel-Aviv 
University, Tel-Aviv; see Materials and Methods for the procedure). Pictures of liveTg:GnRH3-
EGFP embryos taken at 48 hpf developmental stages using Nikon C2
+ ™ 
Confocal Laser  
Scanning Microscope (CLSM) display a GnRH3 fibers network composed by: two GnRH3 
somas detectable close to olfactory placodes and branch of axons departing from these perikarya 
that form a pallium commissure and cross at the level of the optic chiasm to innervate retina 
(Figure 34 A). 
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Figure 34: A ventral view of head of ZF Tg:GnRH3-EGFP living embryos at 48 hpf, taken using confocal laser-
scanning microscope. B GnRH3 network at 48 hpf described in literature (adapted from  Abraham et al., Gen Comp 
Endocrinol. 2009) 
 
Transgenic fish were injected with prokr1aSPL1, prokr1bSPL2 and Ctrl-MO (a morpholino 
sequence without target inside ZF genome, used as control for off-target effects). Pictures were 
collected at 48 hpf developmental stage using a Nikon C2
+ ™ 
CLSM. 
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Figure 35: A: ZF GnRH3 network at 48 hpf described on literature (adapted from Abraham et al., Gen Comp 
Endocrinol. 2009). B: Tg:GnRH3-EGFP embryos at 48 hpf injected with Ctrl-MO morpholino; C: Tg:GnRH3-
EGFP embryos at 48 hpf injected with prokr1aSPL1 morpholino; D: Tg:GnRH3-EGFP embryos at 48 hpf injected 
with prokr1bSPL2 morpholino. 
 
Analysis of pictures revealed that in embryos injected with prokr1aSPL1 morpholino (Figure 35 
C) GnRH3 network seems to be comparable with uninjected (Figure 34 A)  or Ctrl-MO (Figure 
35 B). On the contrary, injected embryos prokr1bSPL2 showed alterations in the normal 
architecture of GnRH3 network (Figure 35 D). In particular GnRH3 fibers departing from GnRH 
somas seem to be less in number, and their route looks generally disorganized, especially at level 
of pallium commissure and optic chiasm. Moreover, no fibers innervate retina and signal in this 
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location and in the hypothalamus the signal looks faint (Figure 35 D). All these defects are 
noticeable comparing prokr1bSPL2 injected embryos both with Ctrl-MO and prokr1aSPL1 
injected embryos. 
 
Knockout of prokr1b 
To confirm the defects observed during prokr1b knockdown experiments, we crossed 
prokr1b
ct814/ct814 
(provided by prof. David Prober, Caltech Institute, US-CA, see Materials and 
Methods) with Tg:GnRH3-EGFP. Fish of prokr1b
ct814/ct814
 KO line contains a mutation in 
prokr1b gene that generate a frameshift and a premature stop codon at amino acid 13. The 
resulting protein is composed only by 13 of 396 amino acids of the normal WT protein, lacking 
fundamental structural domains. 
 
Figure 36: Pictures are ventral view of head of 48 hpf living embryos taken using confocal laser scanning 
microscope (Leika TCS SP8®). A: Tg:GnRH3-EGFP embryos. B:  Tg:GnRH3-EGFP/prokr1b
ct814/ct814
 embryos. A1: 
detail of GnRH3 fiber network of Tg:GnRH3-EGFP. B1: detail of GnRH3 fiber network of Tg:GnRH3-
EGFP/prokr1b
ct814/ct814
. 
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Pictures of Tg:GnRH3-EGFP/prokr1b
ct814/ct814
 embryos at 48 hpf display alterations in GnRH3 
network (Figure 36 B-B1), similarly to what observed for prokr1bSPL2 morpholino injection 
(Figure 35 D), with a general disorganization of the fibers at the level of GnRH3 somata and 
pallium commissure. Moreover, there is clearly a lack of signal at the level of optic chiasm were 
GnRH3 fibers usually cross and a reduced fluorescence in the retina of Tg:GnRH3-
EGFP/prokr1b
ct814/ct814
  ZF embryos compared to Tg:GnRH3-EGFP (Figure 35A-A1). 
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Discussion 
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During this PhD project, we conducted a genetic screening of 12 CHH-related genes on 512 
CHH patients. This study represents a genetic screening conducted on the largest CHH cohort. 
Data analysis shows the presence of 204 variants in 32.2% of clinical cases, 140 of them (67.8%) 
were missense variants. Examination of variants distribution in the cohort underlined how in our 
clinical records FGFR1 resulted the most frequently involved gene with 12.5% of patients 
carrying allelic variants on this gene, followed by PROKR2 (7.5%), GNRHR (6.3%), KAL1 
(5.6%) and TACR3 (4.8%). These percentages are consistent with results presented in other 
studies
12,14,38,40,59,69,177
. Calculation of oligogenicity rate, represented by patients carrying digenic 
mutations, in our cohort display a value of 4.6% which is even higher if compared to 2.5% 
estimated by Sykiotis and colleagues
69
. Thus, the present study, that is including the largest 
cohort ever sequenced for multiple genes, is confirming the conceptual shifting of CHH from 
monogenic to oligogenic disease. Moreover, our study is also confirming that oligogenicity is 
strictly dependent from the number of genes analyzed and sample size. Indeed, passing from 8 
genes screened in 397 CHH patients (Sykiotis) to 12 genes in 512 patients in the present study, 
the rate of oligogenicity increases from 2.5% to 4.6%. Nevertheless, oligogenicity doesn`t give 
us information about molecular mechanisms by which oligogenic interactions cause isolated 
GnRH deficiency. Two hypotheses have been proposed: one is that mutations could act 
independently during different developmental stages, such that their additive effects compromise 
the ontogeny of GnRH neurons and/or pituitary gonadotropes sufficiently to impair sexual 
maturation and fertility. Otherwise, mutations may have a synergistically effect on the same 
ligand/receptor pair or signaling pathway. It is impossible to unequivocally distinguish between 
these two models; this is because the precise role of the known disease genes in the regulation of 
GnRH biology still requires further elucidations
69
.  
Among the genes involved in CHH, we focused our attention on the PROKR2 gene, which is one 
of the most frequently involved gene in our series, and which still presents many open issues 
regarding its involvement in the pathogenesis of CHH. Prokineticin pathway is known to have an 
important role during GnRH neurons migrations. The association between PROKR2 and CHH 
came by the work of Matsumoto and colleagues in 2006, where they described that homozygous 
Prokr2 KO mice, but not heterozygous, displayed abnormal development of the olfactory bulb 
and reproductive system, a phenotype that remind to KS
103
. These firsts indications suggested 
that PROKR2 was a gene associated to KS and that only defects on both alleles could affect 
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GnRH migration and, by consequence, lead to KS. Nevertheless genetic screening conducted 
during the last years revealed that mutations on PROKR2 gene were found both in KS and nCHH 
patients and mostly in heterozygous state
22,178,179
 bringing to a reconsideration of its pathogenetic 
mechanisms. Furthermore, in vitro studies of reported missense mutations demonstrated a 
deleterious effect on PROKR2 signaling in transfected cells, but the same mutations have been 
also found in apparently unaffected individuals
20,180
. Taken together, these data underline how 
PROKR2 role in the pathogenesis of CHH and the functional impact of missense PROKR2 
variants has not been fully characterized. Genetic screening conducted in our cohort identified 17 
PROKR2 rare variants (Minor allele frequency, MAF<0.01) in 37 patients. Similarly to other 
studies present in literature, the majority of patients (35) presented variants in heterozygous state; 
only two, one KS and one nCHH, presented p.R85H variant in homozygous state. Moreover, 
among 37 CHH patients affected by mutation in PROKR2, 11 displayed anosmia (KS) but 26 
had a normal sense of smell (nCHH), confirming that mutations in PROKR2 are not exclusively 
associated to KS. Interestingly, we identified 4 novel variants in our cohort (p.G70S, p.D99N, 
p.C208S and p.M278K). All 4 variants were single-nucleotide polymorphism (SNPs) missense 
variants. To better elucidate the molecular mechanisms by which missense mutation affect the 
signaling of PROKR2, we conducted in silico and in vitro experiments on these novel variants 
and p.R47W, p.M64V, p.R85H and p.P290S, 4 already reported variants which lack extensive 
functional studies. In silico analysis of chosen variants using software for prediction of the 
possible impact of an amino acid substitution on the structure and function of a human protein 
(Sift, Provean, Polyphen and MutationTaster) resulted in a unanimously deleterious effect 
verdict for all 4 novel variants and for p.R85H and p.P290S, suggesting an important role of 
these amino acids residues for the protein integrity. Indeed, algorithms of these prediction 
softwares are mainly based on alignment and comparison of amino acid sequences of the 
selected protein between multiple species to identify the most conserved, and thus more 
important, amino acids. Same analysis conducted on p.R47W and p.M64V predicted a tolerated 
effect for both, even though MutationTaster  software signaled a possible disease causing effect 
for p.M64V. PROKR2 is a class A member of GPCR; as explained in the introduction, this 
receptor is an integral membrane protein consisting of 7 trans-membrane domains coupled with 
G proteins. Its 3D structure was modeled on crystal structures of rhodopsin and ß2-adrenergic, 
two G protein-coupled receptors belonging to the same subfamily of PROKR2
106
. When a ligand 
92 
binds to the extracellular domain of GPCR, it causes a conformational change in the GPCR, 
which allows it to activate an associated G protein and triggering intracellular pathways. There 
are two principal signal transduction pathways involving the G protein–coupled receptors: the 
cAMP signal pathway (Gs-pathway) and the phosphatidylinositol signal pathway (Gq-
pathway)
181,182
. Previous in vitro studies have demonstrated how missense variants can affect 
both receptor membrane-trafficking and signaling activation of PROKR2 differently or 
selectively 
24,106,183
. Basing on these evidences, we structured our study evaluating receptor 
membrane-targeting and intracellular Gs/Gq pathways activation of identified PROKR2 variants. 
 
Receptor membrane-trafficking 
FACS assay performed on not-permeabilized HEK293T cells transfected with PROKR2 variants 
plasmids revealed reduced membrane expression levels of the receptor for all variants. This 
impairment is more severe in the case of p.G70S, p.C208S, p.M278K and p.P290S variants with 
expression values comprised between 5%-17% respect to PROKR2 wild-type (WT) levels. For 
the remaining 3 variants, p.R47W, p.M64V and R85H, expression levels indicate that 50% of the 
protein reach cellular surface. To assess that these variable membrane expression was not due to 
different transfection efficiency of PROKR2 variants plasmids, we performed a Western Blot 
assay. Densitometric analysis of monomeric forms (45 KDa) of PROKR2 WT compared to 
PROKR2 variants displayed similar intensity levels validating FACS data. Interestingly, Western 
Blot analysis revealed another band at an apparent molecular mass approximately twice than the 
monomer (72–95 kDa). A band with the same molecular mass was already described in 
Marsango and colleagues article in 2011 as dimeric form of PROKR2
176
. Differently from 
previous densitometric analysis, results revealed a different intensity among variants with 
p.G70S, p.C208S and p.P290S that displays the lowest intensity, suggesting a possible 
impairment in dimerization process for these variants. To evaluate intracellular localization, we 
conducted an immunofluorescence assay. Images obtained displayed a membrane fluorescent 
signal comparable to PROKR2 WT for p.R47W, p.M64V, p.R85H and p.D99N. On the contrary, 
a strong intracellular signal close to the nucleus was observed for p.G70S, p.C208S, p.M278K 
and p.P290S. The localization of intracellular signal suggests, for these variants, a detainment in 
Golgi or endoplasmic reticulum. These data are in accordance with FACS analysis and confirm a 
strong alteration in membrane-trafficking for p.G70S, p.C208S, p.M278K and p.P290S variants. 
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Intracellular Gq/Gs pathway 
Evaluation of intracellular signaling process in chosen variants display a strong impairment of 
both Gs/Gq-pathways for p. G70S, p.C208S and p.P290S variants that, in the case of Gs-
pathway, is a total absence of cAMP accumulation. Differently, variants p.R47W, p.M64V and 
p.R85H present for both assays an Emax levels that are about 50%, indicating a reduced 
functionality for both signaling pathways. Interestingly, p.D99N and p.M278K variants showed a 
differential activation of intracellular pathways with Gs pathway strongly impaired, and Gq-
pathways that retain half of the functionality compared to PROKR2 WT.   
Thus, altogether, analysis of the data obtained by our FACS, cAMP and IP1 assays allowed us to 
arbitrarily divide variants on three main groups, basing on the functionality of membrane 
trafficking and intracellular pathways.  
 
  
Table 7: Comparison between membrane expression levels (FACS) and Gs/Gq pathways ativation. Red color 
represent variants with strong impairment of both membrane-trafficking and intracellular pathways. Green variants 
with mild impairment for both processes and yellow variants that present a strong impairment for Gs but not for Gq 
pathways.  
Looking at these results, the nature of amino acids substitution and domain localization, we 
postulated a pathogenic effect for each single variants analyzed. Variants p.R47W and p.M64V 
and p.R85H presented a moderate membrane expression and are able to maintain at least 50% of 
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their intracellular pathway functionality (Green in Table 7). For p.M64V, this could due to the 
fact that both methionine and valine are hydrophobic amino acids, so substitution don’t involve 
changes in the charge and could not impact on protein stability. Moreover, their side chains are 
less reactive, and rarely are involved in protein functionality. These observations are in 
accordance with data reported in literature. Indeed, a study conducted in 2012 showed how this 
variant was found associated with p.L173R, a variant known to be deleterious and prevalent 
among GnRH-deficient patients of diverse geographic and ethnic origins
184
. Therefore, is it 
possible that p.M64V mutation alone isn`t enough to lead to a CHH clinical phenotype, and that 
patients affected by this amino acid substitution presented a mutation in another CHH-related 
gene not investigated in our genetic analysis. Variants p.R85H is located on first intracellular 
loop (ICL1) of PROKR2 protein. Abreu and colleagues demonstrated in a previous work how 
this protein domain is important for receptor function
185
. In this work, they analyze several 
arginine 85 variants reported on literature demonstrating how these mutations interfere only 
modestly with IP1 and p42/p44 MAPK signaling pathways
185
. Results obtained by our assay on 
R85H confirm literature data and, in addition, demonstrate that also Gs-pathway is less affected 
by this mutation. Analysis of p.G70S, p.C208S and p.P290S variants displayed both a strong 
impairment of membrane-trafficking and lowest (or absent) activation of Gs/Gq pathways (red in 
Table 7). Intracellular detainment observed in immunofluorescence assay could suggest a folding 
problem for these variant proteins, that could not overcome endoplasmic reticulum (ER) quality-
control system
186
. In particular, cysteine residues substituted in p.C208S is localized in 
extracellular loop 2 (ECL2); this amino acid is involved in disulfide bridge with cysteine 128, a 
strongly conserved amino acid residue in GPCRs
187
. Interestingly, p.D99N and p.M278K display 
a different impairment of intracellular pathways, maintaining a moderate activation of Gq-
pathways and a strong reduction of Gs-pathways (yellow in Table 7). For p.M278K, the different 
nature of methionine, a nonpolar hydrophobic residues, and lysine, that is polar and hydrophilic, 
could lead to a different conformation of ɑ-helixes and, by consequence, their interaction could 
modify for example hydrophobic interface between transmembrane domain 5 and 6 (TM5 and 
TM6), two domains that were shown to be involved in regulation, spatial arrangements and 
activity of prokineticin receptor 2 dimers
188
. 
In vitro analysis conducted during this PhD allowed to better evaluate the impact of PROKR2 
missense variants identified during our genetic screening. Moreover, these results confirm, at the 
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same time, what postulated in a previous work conducted in our lab, that assessment of the 
impact of PROKR2 variants on both the cAMP and IP pathways could help to avoid absolving 
mutations that selectively compromise one signaling branch leaving the other intact, and thereby 
to avoid erroneously predicting a reduced risk of disease in the variant-carrying progeny of such 
patients
24
.  
To better characterize the role of the PROKR2 in the CHH pathogenesis and to overcome the 
limits of the KO mouse model, which is not perfectly fitting with the human phenotype, we 
decided to generate a new animal model. Thus, the last part of this project was focused on 
elucidating the role of PROKR2 on GnRH neurons ontogeny processes, taking advantage of the 
ZF model which, as extensively demonstrated by studies conducted by Zohar group, displays a 
high conservation degree of GnRH neurogenesis processes respect to humans
125,166,167
. These 
evidences, together with advantages offered by this model such as fast development, embryo and 
larvae transparent and the availability of Tg-GnRH3-EGFP transgenic line, make ZF a highly 
effective model for studying GnRH neuronal development
125
. Few data were available in 
literature about prokineticin receptors in ZF, so our study started performing a bioinformatic 
analysis. BLAST alignment tools identified two sequences: prokr1a located on Chr. 1 and 
prokr1b located on Chr. 13. Alignment of protein sequences of these two genes displayed for 
both of them an identity about 70% with human PROKR2. However these information together 
with synteny analysis didn`t provide clear information about the orthologs of human PROKR2 
gene in ZF. The possible presence in ZF of two co-orthologs in contrast to a single copy gene in 
humans and other mammals is not uncommon. Indeed teleost lineage, to which ZF belong, 
experienced an additional whole genome duplication soon after divergence from tetrapods
189,190
. 
To better elucidate if prokr1a and prokr1b genes are respectively orthologs of human PROKR1 
and PROKR2, or they are both co-orthologs of either PROKR1 or PROKR2, we evaluated the 
expression of these two genes along ZF embryo development. Real-Time qRT-PCR analysis 
displays different expression levels for the two genes along ZF early developmental stages. 
Comparison of prokr1a and prokr1b expression pattern revealed that prokr1b is the most 
expressed and, most interestingly, it exhibits an increase at 24 hpf that culminate at 72 hph. This 
time window can be comparable with migration time of GnRH3 neurons described on literature 
by Abraham and colleagues
125
 suggesting a possible role for prokr1b during this process. 
Following WISH experiments, performed to measure spatial expression patterns of mRNA, 
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support this thesis. Indeed only prokr1b showed a signal close to olfactory placodes that is 
similarly to what obtained using GnRH3 probe. It is interesting to note that this signal does not 
overlap exactly the GnRH3 signal, suggesting that in ZF prokr1b could not be expressed by 
GnRH neurons like observed in mice for Prokr2
102,178
. Since it is known that human PROKR2 is 
involved in the migration of GNRH neurons, these spatial and temporal overlapping of prokr1b 
could indicate a role of this gene during migration of GnRH neurons. To better assess functions 
of prokr1a and prokr1b genes, we conducted knockdown experiments in ZF model. Results 
obtained revealed that downregulation of prokr1b (prokr1bSPL2) produced defects in the 
GnRH3 fibers network that looked, at 48 hpf, generally disorganized if compared to prokr1a and 
control injected fishes. Nevertheless, observation of discrepancies between knockdown (via 
antisense) and knockout (via genetic inactivation) phenotypes in ZF has recently started a debate 
on zebrafish community, questioning the validity of morpholino knockdown technique
191,192
. In 
order to confirm the function of prokr1b during GnRH3 ontogeny and avoid possible misleading 
interpretation due to toxicity or off-target effect of antisense injection, we generated prokr1b 
knockout model (Tg:GnRH3-EGFP/prokr1b
ct814
/
ct814
). Examination of GnRH3 neurons network 
in this embryo revealed a general misrouting of fibers similar to what observed in prokr1b 
knockdown fish. Moreover, a detailed analysis of Tg:GnRH3-EGFP/prokr1b
ct814/ct814 
phenotype, 
showed the presence in pallium commissure of small dots not noticed before. GnRH3 somata 
migration process is described to start in ZF at 72 hpf (Abraham 2010) excluding that these small 
dots are GnRH3 cells. Instead, similar sphere-shaped structures where described by Matsumoto 
and colleagues in the axons of Prokr2
-/- 
mice as tangles of GnRH fibers
103
, suggesting that the 
small dots observed could represent the same structure. Taken together these results confirm the 
important role of prokr1b during GnRH3 neurons migration and establishing it as the ZF 
orthologous of human PROKR2. Moreover the use of ZF prokr1b KO model in conjunction with 
knockdown experiments of other CHH-related genes, as well as crosses with existing mutant 
lines for other genes important for GnRH neurogenesis (i.e. anos1a/sa1160 or kissr1
-/-
, kissr2
-/- 
193
 ) could provide many new information regarding the early establishment of the forebrain 
GnRH system, the factors controlling this complex developmental event, and its functional 
significance. 
In conclusion, in the last thirty years we have reached a better comprehension of the GnRH 
neurons processes and perturbations that lead to CHH condition. Nevertheless, the large amount 
97 
of idiopathic patients testifies that we are far from fully elucidating these mechanisms. The large 
numbers of gene identified and phenotypic heterogeneity of individual affected by CHH reflect 
the complexity of GnRH system. Only a deep characterization of genes involved in GnRH 
neurons processes combining genetic screening, in vitro and in vivo model could allow us to 
solve this complex puzzle. In this PhD project, we tried to apply this multidisciplinary approach: 
screening the largest cohort of patients we better assess the oligogenic component of CHH and 
identified new variants in PROKR2 gene. Using in vitro assays we were able to study these 
variants and explain how defects in the sequences could affect folding, cell-membrane 
translocation and signaling pathways of PROKR2. Lastly we identified the ZF orthologous gene 
of human PROKR2 (prokr1b), characterized its role during GnRH neurons development and 
generated a ZF knockout model Tg:GnRH3-EGFP/prokr1b
ct814/ct814
, which will be important to 
better characterize the contribution of the prokineticin pathway in the pathogenesis of CHH.  
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